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Abstract 
A series of presumed or confirmed Cryptococcus gattii cases diagnosed between 1999 
and 2003 was compiled through review of records from veterinary laboratories and 
human diagnostic services.  There was a continual increase in the annual number of 
animal, but not human, cases diagnosed; no seasonality was observed.  Animal cases 
exceeded human cases by almost 75% even though it was hypothesized that animal cases 
are more likely to go undiagnosed or unreported when compared to humans.  Animal 
cryptococcosis cases were identified on Vancouver Island prior to 1999 suggesting the 
organism may have emerged in the region prior to its identification as a causative agent 
for human disease; therefore animals may serve as a good sentinel for human 
cryptococcosis infection.  
 
There were 50% more feline than canine cases and disease appeared more commonly in 
middle aged cats and younger dogs.  There was no sex predilection for either species.  
The primary system involved was most commonly respiratory, followed by central 
nervous system (CNS) in both cats and dogs.  There was a higher proportion of CNS 
disease in dogs relative to cats, and cats were much more likely to have subcutaneous or 
dermal masses relative to dogs.  Multivariate survival analysis identified only the 
presence of neurological symptoms as a statistically significant predictor of mortality; 
those animals exhibiting CNS symptoms were over four times more likely to die than 
those never showing neural signs.  A case-control study identified host and environmental 
risk factors for clinical C. gattii infection in dogs and cats suggesting that where an 
infectious agent is not uniformly distributed, individual risk increases when the organism 
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is re-distributed through large scale environmental disturbance, or when the animal has 
increased opportunities for exposure through travel or activity level.   
 
Serum samples and material for fungal culture were collected from dogs, cats, horses and 
terrestrial mammal species residing within the region where clinical cases had been 
diagnosed.  Nasal colonization was identified in squirrels (Sciurus carolinensis), horses, 
dogs and cats.  Most of the animals sampled had no signs of systemic infection however 
asymptomatic infection, defined as the presence of cryptococcal antigen in the 
bloodstream in the absence of clinical symptoms, was identified in a small number of 
dogs and cats.  Fourteen months of follow-up testing of asymptomatic animals revealed 
that animals can progress to clinical disease, remain sub-clinically infected, or clear the 
organism.   
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1. Introduction and Literature Review 
1.1. Introduction 
The term ‘emerging infectious disease’ (EID) is used to describe the expansion of a known 
pathogen to new host species and/or geographic range, or recent identification of a new 
infectious agent.  Emerging infections have been well documented in human medicine (1) and 
are increasingly identified in domestic and wild animals (2, 3) as well as agricultural and wild 
plant species.  Emerging infectious diseases may impact populations locally, regionally or 
globally and effects vary according to relevant host, agent and environment interactions.   
 
Changes in human ecology are a central force influencing EIDs; the emergence of pathogens 
within different cohorts of biota is fundamentally driven by different forms of environmental 
anthropogenic change (2).  Causal factors implicated in emergence include changes in human 
behavior patterns, social organization, demographics, movement, industry and land use in 
conjunction with microbial adaptation that disrupts the host parasite relationship equilibrium 
such that the parasite is favored (2, 4). 
 
In 2001 the public health authorities and veterinary community of southwestern British 
Columbia, Canada recognized an increased incidence of human and animal cryptococcosis (5).  
The cases were largely restricted to Vancouver Island and most isolates were C. gattii serotype 
B; a species classically restricted to tropical and sub-tropical regions of the world.  The 
appearance of C. gattii in Canada constitutes an EID as the known pathogen has surfaced in a 
new geographic region.   
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1.2. Cryptococcus spp. and cryptococcosis 
1.2.1. Taxonomy 
Cryptococcus spp. are  environmental fungi of the phylum Basidiomycota, class 
Heterobasidiomycetes, order Filobasidiales, family Filobasidiaceae (6).  The genus Cryptococcus 
includes over 37 species however only C. neoformans was commonly considered to be 
pathogenic. There were previously three recognized varieties of Cryptococcus neoformans: C. 
neoformans var. grubii (serotype A), C. neoformans var. neoformans (serotype D) and C. 
neoformans var. gattii (serotypes B and C) as well as a hybrid of C. neoformans var. grubii and 
C. neoformans var. neoformans  (serotype AD) (7-9).  Serotypes are based on the antigenicity of 
the capsular polysaccharides.  Recently proposed changes to the nomenclature suggest that C. 
neoformans should be divided into two distinct species including C. neoformans (serotypes A, D 
and AD) and C. gattii (serotypes B and C) based on molecular and mating type characteristics 
(10).  This nomenclature is now widely accepted and will be used here.  
 
Advances in DNA typing methods have led to the identification of eight molecular types based 
on polymerase chain reaction (PCR) fingerprinting, random amplified polymorphic DNA 
analysis and restriction fragment length polymorphism (RFLP) (11-13). Serotypes are consistent 
with the molecular types of C. neoformans var. grubii (serotype A) and C. neoformans var. 
neoformans (serotype D) where serotype A is made up of molecular types VNI and VNII and 
serotype D equates to VNIV.  Serotype AD, the hybrid of C. neoformans var. grubii and C. 
neoformans var. neoformans, corresponds to VNIII.  In contrast C. gattii is comprised of 4 
different molecular types, VGI, VGII, VGIII, and VGIV, which do not correspond well with the 
delineations of serotypes B and C (14).  
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1.2.2. Ecology and Global Distribution of Cryptococcus spp. 
1.2.2.1. Cryptococcus neoformans 
The ecology of C. neoformans var. grubii and C. neoformans var. neoformans are quite similar; 
as C. neoformans var. grubii was only proposed as a distinct variety, separate from C. 
neoformans var. neoformans, in 1999 it is often difficult to discern differing distributions of the 
two varieties in the literature (15).  Historically both varieties of C. neoformans were thought to  
be associated with avian excreta, particularly that of  pigeons (16-22).  It was hypothesized that 
birds feeding on an unidentified host plant could carry the organism in their gastrointestinal tract 
and act as a vector by dispersing yeast cells in their feces. The birds were thought to not be 
clinically affected because their body temperature was above that required for replication of the 
fungi (23, 24).  This hypothesis was challenged by the isolation of both varieties from living and 
decaying vegetation and domestic dust worldwide (20, 21, 25, 26).  Given that avian excreta is 
rich in creatinine and other chemical constituents that promote fungal replication, it is likely that 
the environmental niche of the fungus is vegetation but that it is easily isolated from avian 
excreta because it provides a good media for growth (21, 24). 
 
C. neoformans var. grubii has a global distribution and is the most common cause of human 
fungal meningitis in immunocompromised hosts worldwide (22, 27-32).  C. neoformans var. 
neoformans (serotypes D and AD) is less commonly recovered from the environment or clinical 
cases and appear to be more prevalent in Europe than other parts of the world (32, 33).   
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1.2.2.2 Cryptococcus gattii 
 Cryptococcus gattii has classically been restricted to the tropics and sub tropics of the world (6, 
32).  The first environmental isolation of the organism was from eucalyptus trees (Eucalyptus 
camaldulensis and E. tereticornis) in Australia (34, 35).  Subsequently C. gattii has been 
recovered from material associated with eucalypt species in many other parts of the world 
including California, India and Brazil (20, 28, 36, 37) and  in non-eucalypt tree species from 
tropical and subtropical areas worldwide (28, 38-40).  Most environmental isolates of C. gattii 
have been serotype B, however there are reports of serotype C isolated from almond trees 
(Terminallia catappa) in Columbia and vegetation in southern California (37,40).  It has been 
proposed that dispersal of infectious propagules, the asexual budding yeast or the sexual 
basidiospores, is linked to the flowering of the eucalypt trees as airborne organisms had, prior to 
the collection of Canadian environmental isolates, only been detected under a tree in flower (23). 
 
Some studies suggest that alternative environmental sources of  C. gattii have yet to be 
identified, as molecular types isolated from clinical and environmental samples have been 
different in western and northern Australia (12, 41, 42) and clinical cryptococcosis caused by C. 
gattii has been reported from many regions where an environmental source cannot be discerned, 
including parts of Australia, Africa and Papua New Guinea (12, 41, 43-45). 
 
The regional distribution of human disease caused by C. gattii corresponds largely with the 
distribution of environmental isolates (6, 29, 34).  In an exhaustive study of worldwide human 
clinical cryptococcosis, isolates of C. gattii were not found in Austria, Belgium, Denmark, 
France, Germany, Holland, Italy, Switzerland, and Japan but were identified at an unusually high 
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prevalence in Australia, Brazil, Cambodia, Hawaii, southern California, Mexico, Paraguay, 
Thailand, Vietnam, Nepal and Central Africa (32).  Follow up studies have confirmed the high 
prevalence of C. gattii in tropical and sub-tropical regions including Brazil  (27, 28), Thailand 
(31), Papua New Guinea (43), Venezuela (46), South Africa and Mexico (46). Small numbers of 
human C. gattii cases have been reported from India, China, Taiwan, Peru , Argentina, Rwanda, 
Italy (6, 22, 30, 47, 48).  Cases reported from Europe and non-endemic areas of North America 
are thought to have been acquired elsewhere (6, 32, 49).   
 
In North America C. gattii is considered to be a rarity (32).  The majority of isolates have been 
serotype B (50, 51) with the exception of southern California where serotype C is more prevalent 
(32) and has been isolated from the environment (37).  In Canada, cryptococcosis has been 
reported from most provinces, is classically associated with immunosuppression and caused by 
C. neoformans (52).  Cryptococcus gattii has been isolated once from an AIDS patient in Quebec 
suffering with cryptococcosis (53) however this patient had a travel history to a region where C. 
gattii is considered endemic (37). 
1.2.2 Cryptococcosis 
Cryptococcosis affects humans and animals worldwide and can be caused by C. neoformans or 
C. gattii.  While the exact mode of infection is unknown, it is widely accepted to be through 
inhalation of air-borne organism (23, 54).  Cryptococcus neoformans has been isolated from the 
nasal passages of dogs, cats (55) and koalas (56) in Australia without evidence of infection 
suggesting asymptomatic colonization of the nasal mucosa following environmental exposure.  It 
is not clear what triggers tissue invasion after colonization (6).  Direct inoculation has been 
reported in humans and experimentally in animals (57, 58).  Zoonotic transmission was proposed 
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in one instance in which  the same molecular strain was isolated  from both human and bird; 
however, this may represent shared environmental exposure (59).  The nature of the infectious 
propagule is hypothesized to be the basidiospore or desiccated yeast cells.  Upon entry into tissue 
the desiccated cell becomes rehydrated and acquires a thick polysaccharide capsule, 
basidiospores convert to encapsulated blastoconidia (23).   
 
Clinical disease is dictated by host characteristics and the variety of infecting organism.  C. 
neoformans is isolated most commonly from immunosuppressed individuals (29, 60).  In contrast 
C. gattii is a primary pathogen as it tends to infect immunocompetent hosts.  Even in areas where 
the organism is endemic, C. gattii is rarely isolated as the cause of cryptococcosis in AIDS 
patients (29, 60, 61).  
 
Exposure to environmental sources of the organism is hypothesized to be the primary risk factor 
for clinical disease.  In Australia, the aboriginal populations living in rural and semi-rural areas 
have a high incidence of cryptococcosis caused by C.  gattii and further investigation suggests 
that this is due to a close association with eucalyptus trees (29).  Men in Australia and Papua 
New Guinea were at an increased risk of infection with C. gattii, presumably because of 
increased contact with the organism in the environment (29, 62).  Isolation of C. neoformans var. 
grubii from a home was a significant risk factor for AIDS patients developing cryptococcosis 
(21).   
1.2.2.1 Animal Cryptococcosis 
Clinical cryptococcosis has been reported in many domestic and wild animal species worldwide.  
The variety of infecting organism is often not identified due to financial constraints or the 
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assumption that isolates are geographically restricted and that the agent can be assumed.  There 
are, however, differences in the clinical presentation of the different varieties that are important 
to recognize.  These differences facilitated the identification of C. gattii in British Columbia. 
 
Cryptococcosis is the most common systemic fungal infection in cats (54, 63, 64).  Disease is 
most frequently reported in middle aged cats, but the age range is broad (65).   Males have been 
reported to be affected more commonly than females, with the suggestion that males are more 
likely to be exposed for behavioral reasons (66-68).  Other studies found no sex predisposition 
(65).  Siamese cats appeared to be over represented in one Australian study (67).  Contrary to the 
hypothesis that environmental exposure may be a principal risk factor, the disease is frequently 
reported in ‘indoor only’ cats (65, 66).   
 
Some seasonality in feline clinical cases has been reported. In Australia there was an observed 
tendency for cats to present to veterinarians in the summer (67). In one study in the USA, cats 
presenting to the clinic with cryptococcosis were more likely to be outdoor cats in the warm 
seasons but strictly indoor cats  in the cold seasons  (66).   
 
The three clinical syndromes most commonly reported for feline cryptococcosis include upper 
respiratory tract disease, dermatomycosis, and meningitis (67-69).  Of the three, upper 
respiratory tract infection, specifically nasal cavity disease, is most commonly observed.  
Clinical signs may include nasal or facial deformity, sneezing, nasal discharge, respiratory noise 
or coughing (65, 67, 69).  Respiratory signs are often accompanied by mandibular lymph node 
involvement (67).  Lower respiratory infection is not a common presentation in the cat. 
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 Infection may remain localized to the nasal cavity and sinuses or penetrate through the cribriform 
plate to the central nervous system where it can cause meningitis.  Clinical signs of feline 
cryptococcal meningitis include depression, ataxia, paresis, coma, lumbar pain, behavior 
changes, vestibular signs and seizures (65, 66, 70).  Central nervous symptoms in cats are often 
not a primary presenting sign but secondary to respiratory infection (67).  Other non-specific 
signs including weight loss, anorexia and lethargy are also reported in the cat (65, 66, 69).   
 
Infection from the nasal passages may disseminate hematogenously, often presenting as 
cutaneous lumps or ocular lesions.  Cutaneous and subcutaneous disease may involve single or 
multiple nodules anywhere on the body and has been reported both as dissemination and as a 
primary lesion (65-68, 71).  Ocular lesions commonly include chorioretinitis from hematogenous 
dissemination or optic nerve meningitis causing blindness (63).   
 
The role of immunosuppression in feline cryptococcosis has been debated.  In  an  Australian 
case series of 29 cats, the prevalence of FIV in cases was equivalent to that in the hospital 
population, however, animals with both infections appeared to have more severe disease (67).  In 
a study in the USA, 21% of cryptococcosis cases had concurrent FIV or FeLV infection, 
compared with 1.4% in the general hospital population.  Immunosuppressed cats were more 
seriously affected (66).  Response to therapy has been less successful in immunosuppressed cats 
in both Australia and the USA (67, 68).  Another American case series found cryptococcosis 
cases with concurrent FeLV or FIV infection to have a less successful treatment outcome (65).  
An examination of FIV positive and negative cats in the USA found C. neoformans more 
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commonly in the oropharynx of FIV seropositive cats although no cats had signs of clinical 
disease (72).   
 
Canine cryptococcosis is reported to affect relatively young dogs (73, 74).  Doberman pincers, 
Great Danes and other large breed have been over represented relative to respective hospital 
populations suggesting a potential genetic or behavioral factor involved with infection  (73, 75).  
Unlike cats and humans, there is no apparent sex predilection (73).  In one retrospective study of 
20 canine cryptococcosis cases in Australia, all dogs infected with C. gattii resided in rural or 
suburban environments suggesting that environmental exposure is an important risk factor (73). 
 
The most common presentations of cryptococcosis in dogs are central nervous system, upper 
respiratory, ocular and cutaneous (76).  Many dogs present with meningitis and clinically have 
ataxia, seizures, vestibular disease, cervical pain or tetraparesis (54, 76).  Uncommonly 
cryptococcosis may present as a spinal cord lesion (77).  Nasal cavity infection is less common 
in dogs than in cats, but may present as nasal discharge, stridor, and facial deformity (69, 73, 76).  
It has been hypothesized that nasal cavity involvement is more prevalent than commonly 
reported but that the disease goes undiagnosed in dogs until the central nervous system is 
involved or because the infection disseminates from the respiratory tract more rapidly in dogs 
than in cats (73).  Optic neuritis is the most common cause of blindness in canine cryptococcosis 
cases but chorioretinitis is also often reported (76).  Atypical presentations of canine 
cryptococcosis include pyleonephritis (78) and intra-abdominal masses (79). 
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Cryptococcosis has been reported in many other domestic and wild species.  Goats with upper 
and lower respiratory tract disease have been reported from Australia and Spain (80-82).  Guinea 
pigs have been infected naturally and experimentally resulting in skin and respiratory tract 
lesions (83-85).  Ferrets have been reported to have respiratory, gastrointestinal and dermal 
lesions (86-88).  Llamas with cryptococcal meningitis and alpacas with pneumonia are not 
uncommon (89, 90).  Horses have been reported with cryptococcal pneumonia, rhinitis, 
meningitis, sinusitis and abdominal cryptococcal granulomas (91-96).  Cryptococcus has been 
isolated from the reproductive tract and known to cause abortion in mares (97-99).  Clinical 
disease has been observed in sheep (12).  Mastitis has been reported in goats and cattle (100). 
 
Avian cryptococcosis has been reported worldwide in many species (24, 101-105).  Clinical 
conditions may vary depending on geography and infecting variety; Australian parrots were 
commonly infected with C. gattii as a primary pathogen.  Cases reported from Europe and North 
America had more severe disease and extensive dissemination from the lung to other systems 
(24).  
 
Much research has gone into cryptococcosis in the koala (Phascolarctos cinereus) as their 
association with eucalyptus trees in Australia makes them a species with a high probability of 
exposure (106).  Koalas have been identified to have both clinical disease and sub-clinical 
infections (56, 106-108).  There are numerous reports of cryptococcosis in non-human primates 
including a squirrel monkey (Saimiri sciureus), a common marmoset (Callithrix jacchus), tree 
shrews (Macroscelides proboscides, Tupaia tana and Tupaia minor), patas monkey 
(Erythrocebus patas) and rhesus monkey (Macaca mulatta) (109-112).  Isolation of 
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Cryptococcus species have also been made from a wild fox (Vulpes vulpes) (113), a striped 
dolphin (Stenella coeruleoalba) (114), a bottlenose dolphin (Tursiops truncates) (115) a cheetah 
(Acinonyx jubatus) (116) and an eastern water skink (Eulamprus quoyii) (117). 
 
Cryptococcosis in animals is routinely diagnosed on the basis of histology, cytology and 
serology; fungal culture is less common.  As a result it is often difficult to determine the exact 
geographical distribution of cryptococcal varieties in animal populations.  One study has 
suggested that culture may be less useful in veterinary medicine as C. gattii is commonly thought 
to be restricted to tropical and sub-tropical regions (63).  Where the variety of infecting organism 
has been determined in animals the pattern appears to follow that of environmental isolates and 
clinical human cases (73, 81). 
1.3. Conclusion 
Cryptococcosis is a sporadic disease of humans and animals with a global distribution.  The 
variety of infecting organism has historically been restricted by geography and the pattern of 
clinical isolates follows that of environmental discovery.  The recent isolation of C. gattii 
serotype B from humans, animals and the environment of southwestern British Columbia, 
Canada (118) challenges the previously accepted ecology of this organism and dictates the need 
for investigation into the emergence of the organism in this new environment.   
1.4. Thesis objectives 
The objectives of this study were to document the pattern of clinical C. gattii infection in humans 
and animals of British Columbia from 1999-2003, to describe the clinical presentation, outcomes 
and variables influencing survival of canine and feline C. gattii infections, to identify risk factors 
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for clinical C. gattii infection in dogs and cats residing on Vancouver Island, to identify the 
prevalence, and outcomes, of sub-clinical cryptococcosis and asymptomatic carriage of C. gattii 
in the nasal passages of dogs and cats and to identify terrestrial mammalian wildlife species and 
horses that have been exposed to or infected with C. gattii on Vancouver Island. 
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2. The emergence of Cryptococcus gattii in British Columbia, 
Canada: 1999-2003 
2.1. Introduction 
In 2001, an increased incidence of cryptococcosis was identified on southern Vancouver Island, 
British Columbia (BC), Canada.  All preliminary animal and human isolates available for culture 
from BC were C. gattii serotype B; clinical disease was recognized in humans, dogs, cats, ferrets, 
porpoises, and llamas resulting in the first multi-species outbreak of cryptococcosis (1).  The 
following chapter documents the descriptive epidemiology of this outbreak of C. gattii in 
humans and animals as it emerged as an important pathogen in the temperate climate of BC 
between 1999 and 2003. 
2.2. Methods 
2.2.1. Human Cases 
Human cases diagnosed between January 1999 and December 2003 were identified by the BC 
Centre for Disease control both retrospectively, through the Public Health Information System 
(PHIS), and prospectively, through reporting of microbiologists and physicians.  The human case 
definition was specific for C. gattii and required clinical symptoms of cryptococcosis and 
isolation of C. gattii from a normally sterile site, or HIV negative status with clinical evidence of 
cryptococcosis and one of: isolation of Cryptococcus spp. of unknown variety from a normally 
sterile site, cryptococcal organism visualized in cerebral spinal fluid (CSF), cryptococcal antigen 
titer >1:8 in the CSF or histological identification of the organism.  Probable cases had clinical 
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symptoms and isolation of C. gattii from sputum with no other causal organism present.  Case 
data collected included location of residence, date of laboratory diagnoses, and microbiological 
findings.   
2.2.2. Animal Cases 
Animal cases diagnosed between January 1999 and December 2003 were identified 
prospectively and retrospectively through local veterinarians, record reviews and case reporting 
from private and public veterinary diagnostic labs.  A confirmed case of animal cryptococcosis 
due to C. gattii required clinically compatible illness and culture of C. gattii from a normally 
sterile site.  A probable animal case included any animal residing on or with a travel history to 
Vancouver Island in the previous two years with clinically compatible illness and a laboratory 
confirmed diagnosis of cryptococcosis by one of: cytology, histopathology, serum or CSF 
cryptococcal antigen titer ≥ 1:2.  Upon receipt of owner and veterinary consent, medical records 
or case summaries were obtained.  Data collected included geographic location of primary 
residence, date of diagnosis and microbiological findings.    
2.2.3. Microbiology 
Culture material from clinical samples were submitted to Dr. Karen Bartlett at the University of 
British Columbia School of Occupational and Environmental Hygiene where there were plated 
onto Bird Seed Agar and incubated at 30oC.  Plates were checked for growth daily for ten days 
before being regarded as negative.   Colonies conforming to cryptococcal morphology were 
serotyped using capsular antibodies (Crypto-check, Iatron Laboratories, Tokyo, Japan).   
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2.2.4. Geographical Analysis 
ArcView® 3.2 (Environmental Systems Research Institute Inc, Redlands, CA) was used to map 
the average annual incidence of human, canine and feline cases per 100,000 individuals by local 
health areas on Vancouver Island.  Canine and feline populations were estimated by converting 
human census data (Statistics Canada, Census of Canada, 2001. Ottawa, ON) to animal 
population using a factor of 0.58 dogs and 0.66 cats per household (2).  Geographical analysis 
focused on Vancouver Island; mainland cases with and without travel histories were excluded 
from maps as no relevant denominator data was available.   
2.3. Results 
One hundred and fifty six animal (63 confirmed and 93 probable) and 91 human (51 confirmed, 
38 probable, 2 of unknown classification) cases were identified and met the inclusion criteria 
between January 1999 and December 2003.  The majority of animal cases were feline (figure 
2.1) or canine but cryptococcosis was reported in Dall’s and harbour porpoises (Phocoenidae 
dalli, Phocoena phocoena), llamas (Lama glama), three avian species (eclectus parrot, Eclectus 
roratus, lesser suphur-crested cockatoo, Cacatua sulphurea, cockatoo of unknown species), 
domestic ferrets (Mustela putorius furo) and a horse.  In five animal cases the species of animal 
was unknown.  These animals are most likely canine or feline cases as material was submitted 
from small animal practices. 
 
Date of diagnosis was obtained for 148 animal cases and 89 human cases.  Figure 2.2 shows the 
number of confirmed and probable animal and human cases diagnosed by year.  Confirmed and 
probable case counts by month are reported in figure 2.3.   
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Location of primary residence was available for 140 animals (73 feline, 51 canine, 16 other 
species) and all 91 human cases.  The average annual incidence of cryptococcosis per 100,000 
individuals by local health areas on Vancouver Island are shown in figure 2.4 for humans and 
figures 2.5 and 2.6 for dogs and cats respectively.  Mainland cases were not mapped.  Two dogs 
with cryptococcosis resided on the mainland but had a travel history to the island in the previous 
year.  Two cats and one llama from the mainland had no travel history to the island. 
2.4. Discussion 
The identification of C. gattii in Canada is an important finding that challenges the previously 
accepted ecology and epidemiology of the organism.  Retrospective analysis of human 
cryptococcosis in British Columbia prior to 1999 failed to reveal any cases that met the inclusion 
criteria for this study suggesting the emergence of disease in this region in 1999 (McDougall, 
unpublished).  In contrast, review of animal cryptococcosis cases identified through two 
diagnostic labs for the province revealed four cases of cryptococcosis in animals between 1995 
and 1999, three of which were from veterinary clinics on Vancouver Island.  Fungal culture is 
not routine in veterinary medicine so it is unknown if these cases were C. gattii, however given 
the relatively low animal population on Vancouver Island relative to the remainder of the 
province serviced by this diagnostic laboratory  these cases suggest an earlier emergence of the 
organism within the region.   
 
The number of human cases increased from 1999 to 2002 but remained relatively stable in 2003.  
Human case counts correspond to 8.5 per million people in 1999, 26 per million in 2000, 24 per 
million in 2001, 35 per million in 2002 and 2003; the incidence of human cryptococcosis in BC 
prior to 1999 was 1-2 per million (McDougall, unpublished).  In contrast, animal cases increased 
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consistently with a sharp jump in 2003.  This sharp increase may reflect increased testing for the 
agent or better reporting by veterinarians.  As practitioner awareness grew, more veterinarians 
were testing specifically for cryptococcosis which shows few abnormalities on routine 
hematology (3).  Although record reviews were conducted at the two largest diagnostic labs in 
the province, cases that were diagnosed in clinic or by different laboratories may not have been 
recorded.  The total count of animal cases likely underestimates the true incidence of disease in 
the area (3). 
 
Examination of the human and animal cases by month failed to show a seasonal pattern of 
disease.  Some seasonality in feline clinical cases has been reported in Australia where there was 
an observed tendency for cats to present in the summer (4) and in the USA where cats presenting 
with cryptococcosis were more likely to be outdoor cats in the warm seasons and in the cold 
seasons were strictly indoor cats (5).  Seasonal trends in the incidence of human cryptococcosis 
(6) or other species (7) have not been reported.   
 
Regardless of the potential underestimation of animal cases there were significantly more clinical 
cases in animals compared to humans within this and previously reported time periods (3).  
Human cases were identified through computerized health records while animal cases were 
sought out by contacting veterinarians and diagnostic facilities individually.  While it may be 
argued that the animal investigation involved more personal contact with diagnosticians, the 
human PHIS system and database compiled by the British Columbia Center for Disease Control 
was exhaustive and it is highly unlikely that laboratory diagnosed human clinical cases were 
missed.  Within animal species there appears to be some degree of species susceptibility or 
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variation in species exposure as the incidence of disease is reportedly greater in cats than in dogs 
(8).  Estimates of the incidence of cryptococcal disease in animals relative to humans worldwide 
are largely imprecise or unavailable as there is no formal surveillance for the disease.   
Therefore, it is difficult to evaluate the relative susceptibilities of species on Vancouver Island.  
In Australia, koalas have been successfully used to identify geographic areas with a high-grade 
presence of C. gattii in the environment (9, 10), however it is difficult to distinguish species 
susceptibility from increased environmental exposure.   
 
Human and animal cases are clustered on the east coast of the island within the Coastal Douglas-
fir (CDF) biogeoclimatic zone.  This area encompasses a small part of southeastern Vancouver 
Island, some small islands in the Straight of Georgia and a narrow strip of the adjacent mainland.  
The CDF region is characterized by its wet, mild winters and dry, warm summers (11).  Since 
2001 C. gattii has been repeatedly and consistently isolated from soil, air and vegetation within 
the CDF zone (12, 13).  Maps of average annual incidence of cryptococcosis for humans, dogs 
and cats reveals a similar pattern of cases clustered on the southeastern coast of the island.  
Feline cases appear to be restricted to fewer local health areas while canine and human cases 
were more evenly distributed.  This may reflect the travel pattern of humans and dogs relative to 
cats.  Census data is not collected for companion animals in Canada.  As a result population 
denominators were calculated based on a survey done by the American Veterinary Medical 
Association (AVMA) to estimate the population of companion animals within a community.  
While data was provided for different regions of the United States, the national average was used 
for this Vancouver Island study as no single region in the United States is representative of the 
Vancouver Island demographic.  While this statistic may under or overestimate the actual pet 
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population on the island, the AVMA study is the most comprehensive survey of pet populations 
in North America and thus the least subjective means of estimating pet populations in the region.  
Calculation of incidence in this way facilitates a crude comparison of incidence between regions 
of Vancouver Island but the extrapolation of this conversion factor should be made with caution 
when evaluating variables such as population risk. 
 
By December 2003 there were at least three animals but no people diagnosed with C. gattii 
serotype B in the lower mainland area of British Columbia that lacked travel history to the 
affected biogeoclimatic zone on Vancouver Island.  Given the potential for earlier onset of 
clinical disease animals and documented higher rate of disease in animals compared to humans 
these cases may reflect environmental organism in a larger area than previously considered.  At 
the time of writing no environmental source of C. gattii has been reported on the mainland of 
British Columbia. 
 
Molecular research has identified eight molecular types within pathogenic species of 
Cryptococcus spp. (14-17).  Serotypes agree with molecular types in both varieties of C. 
neoformans however studies indicate that the C. gattii serotypes B and C do not correlate to the 
four identified molecular types for this variety (17). This variation emphasizes the importance of 
molecular typing over serotyping in epidemiology studies.  Investigation into the molecular type 
of isolates from humans, animals and the environment will provide valuable information on the 
epidemiology of the organism in this region. 
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Spatial, temporal and microbiological data from clinical cases on Vancouver Island reflect the 
linked nature of the emergence of clinical disease caused by C. gattii serotype B within this 
temperate region of the world.  Further molecular and epidemiological studies are needed to 
identify risk factors and other variables related to the emergence of this organism within a 
previously unexpected area.  
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Figure 2.1: Confirmed and probable C. gattii cases by animal species on Vancouver Island from 
 January 1999 to December 2003 
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Figure 2.2:  Confirmed and probable human and animal C. gattii cases on Vancouver Island by 
year from January 1999 to December 2003 
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Figure 2.3: Confirmed and probable human and animal C. gattii cases on Vancouver Island by 
month from January 1999 to December 2003  
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Figure 2.4: Average annual incidence of human cases per 100,000 people by local health area on 
Vancouver Island, BC 
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Figure 2.5: Average annual incidence of canine cases per 100,000 by local health area on 
Vancouver Island, BC 
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Figure 2.6: Average annual incidence of feline cases per 100,000 by local health area on 
Vancouver Island, BC 
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3. Clinical characteristics and predictors of mortality for 
Cryptococcus gattii infection in southwestern British 
Columbia, Canada 
3.1. Introduction 
Cryptococcosis is a fungal disease found worldwide in human and animal populations.  The 
causative agent is the organism Cryptococcus spp. which is considered infectious only as a 
desiccated yeast cell or basidiospore as found in the environment (1).  The genus Cryptococcus 
includes over 37 species however only C. neoformans and C. gattii are commonly considered to 
be pathogenic.  Conventional nomenclature included three recognized varieties of Cryptococcus 
neoformans: C. neoformans var. grubii (serotype A), C. neoformans var. neoformans (serotype 
D) and C. neoformans var. gattii (serotypes B and C) as well as a hybrid of C. neoformans var. 
grubii and C. neoformans var. neoformans  (serotype AD) (2-4).  Recently proposed changes to 
the taxonomy suggest that C. neoformans should be divided into two distinct species including 
C. neoformans (serotypes A, D and AD) and C. gattii (serotypes B and C) based on genetic 
variability and lack of evidence for genetic recombination between the two varieties (5).   
 
Historically the organism responsible for clinical disease has been thought to be determined by 
environmental and ecological factors.  Cryptococcus gattii had been restricted to the tropics and 
sub tropics while C. neoformans has a global distribution (1, 6).  The pattern of clinical disease 
corresponds with the distribution of the ecologically limited environmental isolates (1, 7, 8).  The 
epidemiology of cryptococcosis depends largely on the species of infecting organism as C. 
neoformans infects predominantly immunocompromised hosts while C. gattii has not been 
associated with a suppressed immune system (1, 9).  Historically only C. neoformans has been 
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routinely isolated from animals or humans in Canada without a travel history to a region in 
which C. gattii is endemic. 
 
In 2001 the public health authorities and veterinary community of southwestern British 
Columbia (BC), Canada recognized an increased incidence of human and animal cryptococcosis 
(10, 11).  Cryptococcus gattii serotype B was isolated from human and animal cases associated 
with the outbreak and affected individuals had a history of travel to, or residence on Vancouver 
Island (10, 11).  Investigation into the environmental niche of the fungus in Canada revealed the 
same organism in the environment within the Coastal Douglas Fir biogeoclimatic zone on the 
south east coast of Vancouver Island (12, 13).  The following case series describes the clinical 
presentation, outcomes and variables influencing survival of canine and feline cryptococcosis 
cases caused by C. gattii in British Columbia between January 1999 and December 2003. 
3.2. Materials and methods 
Feline and canine cryptococcosis cases diagnosed between January 1999 and December 2003 
were identified both prospectively and retrospectively from May 2003 through active 
surveillance and passive reporting of cases by BC veterinarians, private veterinary laboratories 
and the Animal Health Center at the Ministry of Agriculture, Food and Fisheries.  A confirmed 
case of cryptococcosis due to C. gattii required clinically compatible illness and culture of C. 
gattii from a normally sterile site.  A probable case included any animal residing on or with a 
travel history to Vancouver Island in the previous two years with clinically compatible 
symptoms and a laboratory confirmed diagnosis of cryptococcosis by one of: cytology, 
histopathology or a latex cryptococcal antigen agglutination test titer > 1:2 from serum or 
cerebral spinal fluid. 
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 Upon receipt of owner and veterinary consent, medical records or case summaries were obtained 
for animals included in the study.  Information collected included geographic location, animal 
signalment, medical history, date of presentation and diagnosis, presenting complaint and 
physical exam findings, diagnostic procedures and treatment.  Outcomes were evaluated by 
contacting primary veterinarians between six months and two years after diagnosis.   
3.2.1. Statistical analysis 
Results of the medical record reviews were stratified by species.  Based on veterinary records an 
animal was classified by presenting complaint and physical exam findings into a category of 
principal body system involved.  These categories included respiratory, central nervous system 
(CNS), subcutaneous mass or dermal lesions, gastrointestinal, generalized illness or other.  
Subsequent progression of disease to additional body systems were classified as secondary and 
tertiary systems based on chronological order and veterinary evaluation.  Descriptive and 
comparative statistics were computed using SPSS 12.0 (SPSS Inc., Chicago, Il., USA).   
 
Survival analysis was conducted on all cases presenting with respiratory or CNS symptoms using 
SPSS 12.0 (SPSS Inc., Chicago, Il., USA).  Endpoints were determined to be death due to or 
euthanasia because of cryptococcosis.  Cases lost to follow-up or still alive at the time of follow-
up were censored by the date they were last seen by the diagnosing veterinarian or last date 
known to be alive.  A dichotomous variable, CNS symptoms, was created for animals that 
presented with or progressed to CNS disease. To evaluate the potential role of 
immunosuppression on survival, three individual variables were created; the presence or absence 
of significant illness within two years of diagnosis, history of steroids in the year prior to 
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diagnosis and the combination of steroids and disease history into a dichotomous variable 
representing any potential medical or pharmacological induced immunosuppression.  These and 
other categorical variables including sex, species, antifungal therapy received, primary 
presenting system, and location of clinic were evaluated individually using the Kaplan-Meier 
survival analysis.  Age, a continuous variable, was evaluated independently using Cox 
Regression survival analysis.   Variables with p < 0.20 on the Log rank test were included in a 
multivariate Cox Regression survival analysis.  Within the Cox Regression model only variables 
with p<0.05 on the Wald test remained in the model. 
3.3. Results 
3.3.1. Feline 
Seventy-eight feline cases suggestive of C. gattii infection were identified between January 1999 
and December 2003.  Of these, 26 were confirmed C. gattii serotype B on culture and 52 were 
probable based on diagnosis, location and travel histories.  Case information and primary system 
involvement was obtained for 72 and 73 cases respectively.  The median age at diagnosis was 7.3 
years (minimum 1.2, maximum 14.7 years).  There were 41 female (3 intact, 38 spayed) and 31 
male (3 intact, 28 neutered) cats.  
 
The initial presenting complaint and veterinary evaluated primary system involved is presented 
in tables 3.1 and 3.2 respectively.  Twenty (27%) cats were presented to the veterinarian for 
generalized illness including weight loss, anorexia and lethargy or behavioral changes.  Twenty 
(27%) were presented for respiratory problems including nasal discharge, increased respiratory 
sounds or effort, coughing and sneezing.  Twenty (27%) presented for owner identified skin 
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lumps and 12 (17%) presented for CNS disease including ataxia and seizures.  One cat (1%) 
presented for dental disease.   
 
Upon veterinary examination the respiratory tract was the primary system involved in the 
majority of cases (40 cats, 56%).  Many of the skin lumps identified by owners were enlarged 
submandibular lymph nodes related to upper respiratory tract infection.  Nineteen cats (26%) 
were classified as CNS cases and 14 cats (19%) had subcutaneous lumps or dermal lesions.  
Eight (20%) cats presenting with clinical respiratory tract disease progressed to central nervous 
system disease, one cat with a sub-cutaneous mass on its dorsal thorax progressed to central 
nervous system disease. 
 
Diagnosis was based on cytology, serology and histology in 42%, 31% and 28% of the cases 
respectively.  Serology titers ranged from 1:2 to 1:20,000 and there was no pattern between titer 
value and organ system involvement.  One cat had a negative titer but chronic nasal discharge 
revealed Cryptococcus spp. on cytologic examination.   
 
Fifteen (21%) cats had a reported history of underlying illness that including feline leukemia 
virus (2), hyperthyroidism (4), feline lower urinary tract disease (3), irritable bowel syndrome, 
renal disease, vaccine reaction within year of diagnosis, allergies, feline asthma and chronic 
ectoparasite infestation.  Eight cats had received steroids in the year preceding diagnosis.   
 
Twenty-three (32%) cats were diagnosed post-mortem or euthanized upon diagnosis.  Treatment 
was attempted in 49 (68%) cases.  Of those where treatment was initiated 31 (63%) were 
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respiratory cases.  Seven of these respiratory cases were alive at the end of the study and were 
still being treated with fluconazole (3), itraconazole (3), ketoconazole (1) between 5 and 10 
months after diagnosis.  Fourteen respiratory cases died or were euthanized within three days to 
eight months after diagnosis because disease had progressed to the CNS or the animal failed to 
respond to therapy.  Seven respiratory cases were classified as clinically recovered by the 
diagnosing veterinarian.  These animals received fluconazole (4), itraconazole (2) or fluconazole 
with amphotericin B.  Three respiratory cases were lost to follow-up after initiation of treatment.  
 
 Eight (16%) cats receiving therapy had veterinary classified presenting symptoms consistent 
with central nervous system disease.  Three cats were still undergoing therapy with itraconazole 
between five and 11 months after diagnosis.  Two cats died within two weeks of diagnosis after 
being treated with itraconazole, another three cats were euthanized between two weeks and five 
months of treatment with itraconazole and fluconazole.   
 
Ten (20%) cats with subcutaneous masses received antifungal therapy.  Two of these cats were 
deemed recovered by the diagnosing veterinarian, both had had the masses surgically excised 
and one had received itraconazole for one month following excision.  One cat was still 
undergoing treatment with fluconazole 11 months after diagnosis.  Five cats were euthanized, 
three within one year of diagnosis, one of which had progressed to central nervous system 
disease within two weeks of diagnosis.  The remaining two cats were lost to follow-up.  
Excluding cases lost to follow-up the overall case fatality of cats included in this case series was 
70%.  Of those cases where treatment was initiated the case fatality rate was 55%. 
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3.3.2. Canine 
There were 51 canine cases suggestive of C. gattii serotype B infection identified between 
January 1999 and December 2003.  Nineteen were confirmed C. gattii and 32 cases were 
classified as probable.  Case information was available for 50 cases.  There were 23 males (7 
intact, 16 neutered) and 27 females (4 intact, 23 spayed).  The median age was 2.3 years 
(minimum 5 months, maximum 15.5 years). 
 
The primary presenting complaint and veterinary-evaluated primary system involved is presented 
in tables 3.1 and 3.2 respectively.  Nineteen (38%) dogs were brought to the veterinary clinic for 
respiratory problems.  Reported complaints included nasal discharge, epistaxis, noisy breathing, 
sneezing and coughing.  Fifteen (30%) dogs presented for neurological disease including ataxia, 
neck pain or seizures.  Six (12%) dogs presented for generalized illness including anorexia and 
weight loss and six (12%) dogs presented to the veterinarian for ocular problems, four with acute 
onset of blindness and two with exopthalmous.  Three (6%) dogs were brought in for 
subcutaneous lumps on the head or body. One dog presented for an acute onset of vomiting and 
diarrhea. 
 
Upon examination by the veterinarian, 26 (52%) of the cases were deemed to be respiratory in 
nature, primarily restricted to the upper respiratory tract.  Four dogs presenting with or 
determined to have exopthalmous on veterinary exam all had concurrent upper respiratory tract 
disease.  Twenty-one (42%) dogs were classified as central nervous system cases and two (4%) 
had subcutaneous masses. The single gastrointestinal case was taken to surgery for an 
intusseption caused by an extraluminal cryptococcoma.  Six cases (24%) initially classified by 
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the veterinarian as respiratory progressed to central nervous system disease.  One dog with 
respiratory disease later developed subcutaneous masses.   
 
Diagnosis was made primarily on cytology (44%) or serology (34%) but histology (18%) and 
culture (4%) were also used for diagnosis.  Titers ranged from 1:2 to 1:25,000 and did not 
correlate with presenting complaint or primary system involved. 
 
Six (12%) dogs had a history of underlying disease that could be considered potentially 
immunosuppressive.  These conditions included immune mediated thrombocytopenia (2), mast 
cell tumor, lymphosarcoma, hypothyroid and a ruptured uterus.  Ten dogs had received steroids 
within the year before diagnosis. 
 
Twenty-four (48%) dogs were treated and 26 (52%) were diagnosed post-mortem or euthanized 
upon receipt of diagnosis.  Of those undergoing therapy 15 (63%) were respiratory cases.  Nine 
of the canine respiratory cases were still alive and receiving therapy between five and 13 months 
after diagnosis.  Three dogs were euthanized after commencing treatment, one for diagnosis of 
lymphosarcoma and two for unknown causes.  Two dogs were reported as recovered after four 
and 12 months of therapy with azole antifungals.  One respiratory case was lost to follow-up.    
 
Of the seven (29%) neurological cases where treatment was attempted, two dogs were still alive 
and undergoing treatment with azole antifungals alone or in combination with amphotericin B at 
the time of writing.  Three of the dogs with primary neurological diseases died within one to 
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three weeks of commencing treatment with azole antifungals and or amphotericin B.  Two 
neurological dogs were lost to follow-up. 
 
One dog with a solitary subcutaneous mass underwent surgical excision of the mass and 
recovered with no antifungal therapy.  The dog with the abdominal cryptococcoma was treated 
with fluconazole for 10 months post surgery and was clinically healthy but maintained a 
cryptococcal antigen titer >1:2.  Excluding cases lost to follow-up the overall case fatality of 
dogs included in this case series was 68%.  Of those cases where treatment was initiated the case 
fatality rate was 29%. 
3.3.3. Survival analysis 
Thirty nine feline and 20 canine cases representing animals presenting with respiratory or central 
nervous symptoms and receiving treatment were included in the survival analysis.  Of these 51% 
of canine and 63% feline cases were censored.  On initial univariate analysis only the presence of 
central nervous system disease (p<0.01), primary system involved (p=0.06) and species (p=0.14) 
were significant at the 20% level.  Significant medical history (p=0.52), city of diagnosing clinic 
(p=0.46), sex (p=0.37), steroids in the previous year (p=0.29), antifungal treatment (p=0.86), 
potential immunosuppression (p=0.83) and age at diagnosis (p=0.33) were excluded from further 
models. 
 
Using Cox Regression survival analysis, a model created with species, presence of CNS 
symptoms and primary presenting system revealed that only the presence of CNS symptoms was 
a significant predictor of mortality (p<0.01).  A second Cox Regression model (figure 3.1) 
including only the presence of CNS symptoms found that those animals that present with or 
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progress to neurological disease are 4.3 times more likely to die than those that never show 
neurological symptoms (95% CI for mortality ratio 1.87, 9.89).   
3.4. Discussion 
During the study period, fifty percent more cats than dogs were identified for inclusion in the 
case series.  This result likely represents the differing species susceptibilities to the organism.  
Cryptococcosis is the most common systemic mycoses of cats and, unlike other fungal diseases, 
clinical cryptococcosis has been reported in equal or greater frequency in cats than in dogs (14, 
15).  A previously reported subset of these BC cases identified more cases in dogs however this 
result may be due chance as the time interval was considerably smaller than that of this study 
(16).   
 
As the sex ratio of the underlying population is unknown gender cannot be evaluated statistically 
however there does not appear to be a sex predisposition.  Some studies of cats have identified a 
greater proportion of males affected and suggested that males are more likely to be exposed for 
behavioral reasons, however other studies found no sex predisposition (17-20).  No apparent sex 
predilection has been reported in dogs (21).   
 
As has been observed in other case series, feline cryptococcosis is more common in middle aged 
cats but cats of all ages may be affected.  The age range in this and other case series is wide (17-
19, 22).  In contrast to cats, clinical disease was more common in younger dogs as has been 
previously documented (21, 23).  Breed predisposition could not be evaluated in this case series 
as the underlying population of the region is not known.  In other studies Doberman Pincers, 
Great Danes and other large breed have been over represented relative to respective hospital 
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populations suggesting a potential genetic or behavioral factor involved with infection (21, 24).  
Siamese cats appeared overrepresented in one Australian study (19).   
 
Respiratory disease was the most common syndrome in cats (56%) followed by central nervous 
system symptoms (26%) and subcutaneous or dermal lesions (19%).  While the high proportion 
of respiratory cases is similar to previous studies, the proportion of cats with CNS symptoms 
exceeded those previously reported (17, 19, 22) and may represent a difference in virulence of C. 
gattii compared to C. neoformans which has been more commonly isolated or, based on location, 
assumed to be the causative agent in the other case series.  Central nervous system signs in cats 
have been reported to be secondary to respiratory infection and not a common primary 
presenting sign (19), however, this study had a high percentage of cases presenting for CNS 
disease without a reported history of respiratory symptoms. 
 
The manifestation of cryptococcosis in dogs of British Columbia is very similar to those reported 
from Australia where a retrospective case series identified 55% respiratory cases, 35% central 
nervous system, 5% with disseminated disease and 5% with gastrointestinal symptoms (21).  It 
has been hypothesized that nasal cavity or respiratory involvement is more prevalent than 
commonly reported but disease goes undiagnosed in dogs until the central nervous system is 
involved or the organism simply disseminates from the respiratory tract faster in dogs than in 
cats (21).  Similarly, this study found a greater proportion of canine cases were classified as 
neurological at first veterinary visit when compared to feline cases.  Intra-abdominal masses 
have been reported in dogs but may be considered an atypical appearance of cryptococcosis (25). 
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Only respiratory and CNS cases were included in the survival analysis as the relative number of 
other cases receiving treatment was too low to evaluate meaningfully.  The results of the survival 
analysis reveal that the presence of neurological symptoms was a very strong predictor of 
mortality.  Animals presenting with or progressing to CNS disease were over four times more 
likely to die than those never exhibiting neurological symptoms.   
 
The poor survival in animals exhibiting central nervous system symptoms observed in this study 
may be explained by a number of factors.  Most significant is likely the severity of the disease 
once it has entered the central nervous system (15, 17).  It is also possible that because endpoints 
in this analysis included both death and owner elected euthanasia, treatment may have been 
terminated for reasons other than the animal being moribund.  Such reasons could include cost of 
therapy or owner perceived severity of clinical symptoms and electing humane euthanasia.  
Finally survival may be influenced by treatment initiated.  While antifungal therapy was not a 
significant predictor in the model it is important to note that only the azole antifungals were used 
with enough frequency to influence the model.  For central nervous system cases effective 
therapy requires a drug that can penetrate the blood brain barrier such as amphotericin B, 
flucytosine and fluconazole (14, 18, 21, 26).  Failure to select one of these agents would result in 
a poor response to therapy.  Minimum inhibitory concentration (MIC) work done on a subset of 
cultures from this case series found all isolates were susceptible to amphotericin B but there was 
some intermediate sensitivity and resistance to fluconazole and flucytosine (16).  Amphotericin 
B, the most affordable and potentially efficacious antifungal drug when dealing with CNS cases, 
was largely avoided in these cases out of concern for nephrotoxic side effects.  Newly proposed 
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treatment regimes using amphotericin B need to be considered in attempt to improve animal 
outcomes (14). 
 
Geographic location of diagnosing clinic was evaluated because of potential variation in 
diagnostic procedures by region and variability in environmental load and exposure but was not 
determined to effect survival.  Species alone was not a significant predictor of survival however 
dogs have a higher proportion of central nervous presentations which may indirectly impact 
survival as clinical presentation will influence a veterinarian and owners decision to treat.   
 
The veterinary-identified primary system of involvement did not significantly affect the survival 
model but should be considered clinically important.  The presence of CNS symptoms at any 
point was a very strong predictor of mortality and this variable encompasses any cases who 
present with primary CNS disease.  In this analysis there were few animals presenting with 
primary CNS disease, receiving treatment and then surviving long enough to be included in and 
contribute to the model which may explain why primary system alone was not significant.  
Similarly in a study on the outcomes of cats treated with itraconazole the location of infection 
did not affect outcome, however they also had a very small proportion of primary CNS cases 
(20).   
 
The role of immunosuppression in animal cryptococcosis is unclear.  Neither a history of 
potentially significant illness, corticosteroids in the previous year or a combination of the two 
variables significantly influenced the survival analysis for BC cases.  In a study of cats in 
Australia, the prevalence of feline immunodeficiency virus (FIV) in cases was equivalent to that 
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of the hospital population, however these animals appeared to have more severe disease than 
those without concurrent FIV infection (19).  In contrast, a retrospective study in the USA found 
the prevalence FIV and feline leukemia infection in cryptococcosis cases to be higher than the 
general hospital population and the concurrently infected individuals were more seriously 
affected (18).  Response to therapy has been reportedly less successful in immunosuppressed cats 
in some studies (19, 20) but not in others (17).  The causative agent in most of these studies has 
been identified as or assumed to be largely C. neoformans and not C. gattii.  In humans C. 
neoformans predominantly infects immunocompromised hosts (9) while C. gattii has not been 
associated with a suppressed immune system (1).  Species of Cryptococcus may dictate the role 
of immunosuppression in clinical animal cases.  Based on the results of this study 
immunosuppression does not significantly affect the mortality of dogs and cats with C. gattii 
infection in BC. 
 
This study provides a general summary of important descriptive case characteristics for canine 
and feline cryptococcosis due to C. gattii in BC.  Given the recent emergence and apparent 
persistence of C. gattii in the region veterinarians need to be aware of the primary presenting 
symptoms suggestive of C. gattii infection and variables that may influence outcomes.  The use 
of clinical information from multiple sources puts severe limitations on the type of information 
that can used to summarize case characteristics.  Variation in diagnostic and therapeutic 
techniques dictates broad generalizations of individual animal reports.  Clinicopathologic 
features of a subset of these cases have been reported in more detail elsewhere (16) but clinical 
trials or case series with standardized diagnostic and treatment regimes are needed to better assist 
clinicians in making individual animal diagnoses and treatment decisions. 
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Table 3.1: Owner reported primary presenting complaint for canine and feline cryptococcosis 
 Feline, n (%) Canine, n (%) 
Respiratory 20 (27) 19 (38) 
Central nervous system 12 (16) 15 (30) 
Generalized illness 20 (27) 6 (12) 
Dermal 20 (27) 3 (6) 
Ocular 0 6 (12) 
Gastrointestinal 0 1 (2) 
Other (dental) 1 (1) 0 
 
Table 3.2: Veterinary reported primary organ system involved in canine and feline cases 
 Feline, n (%) Canine, n (%) 
Respiratory 40 (56) 26 (52) 
Central nervous system 19 (26) 21 (42) 
Subcutaneous mass 14 (19) 2 (4) 
Gastrointestinal 0 1 (2) 
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Figure 3.1: Cumulative survival for animals with and without central nervous system symptoms 
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4. Risk factors for clinical Cryptococcus gattii infection in 
dogs and cats on Vancouver Island, British Columbia, 
Canada 
4.1. Introduction 
Cryptococcosis is a sporadic disease found worldwide in human and animal populations.  The 
causative agent is Cryptococcus spp. which is considered infectious only as a desiccated yeast 
cell or basidiospore as found in the environment (1).  The genus includes many species but only 
C. neoformans and C. gattii are commonly regarded as pathogenic.  Cryptococcus neoformans 
has two recognized varieties: C. neoformans var. grubii (serotype A) and C. neoformans var. 
neoformans (serotype D) as well as a hybrid of C. neoformans var. grubii and C. neoformans var. 
neoformans (serotype AD) (2, 3).  Cryptococcus gattii (serotypes B and C) has recently been 
identified as a species distinct from C. neoformans based on genetic variability and lack of 
evidence for genetic recombination between C. neoformans and C. gattii (4). 
 
Cryptococcus gattii had historically been geographically confined to the tropics and subtropics 
while C. neoformans had a global distribution (1, 5); the pattern of clinical disease corresponded 
largely with the ecologically restricted environmental organism (1, 6, 7). Since 1999 C. gattii 
(serotype B) has been isolated from sick people and animals in southwestern British Columbia 
(BC) as well as from air, soil and vegetation samples collected on the south east coast of the 
island (8-11).  These findings are in stark contrast to the organisms previously described ecology 
and associated epidemiology.  
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Prior to the emergence of C. gattii, cryptococcosis was considered a rare disease of companion 
animals in Canada.  Vancouver Island veterinarians were challenged by an increasing number of 
cases and a lack of information on risk reduction measures.  The purpose of this study was to 
identify risk factors for clinical C. gattii infection in dogs and cats residing on Vancouver Island, 
BC.  
4.2. Materials and methods 
4.2.1. Inclusion criteria 
As two previously reported case series of animal cryptococcosis identified a relationship between 
C. gattii infection and southeastern Vancouver Island, BC this area was selected as a focal point 
for the study (8, 11).  Cryptococcosis in animals is not a reportable disease in Canada so incident 
cases of feline and canine cryptococcosis meeting the case definition were identified by 
contacting veterinary clinics on Vancouver Island and private diagnostic laboratories servicing 
BC.  Cases included in this study were identified during two distinct time periods; August 2001 
to February 2002 and May to December 2003.   
 
A confirmed case of cryptococcosis due to C. gattii required clinically compatible illness (12) 
and culture of C. gattii from a normally sterile site.  A probable case included any animal 
residing on or with a travel history to Vancouver Island in the previous two years with clinically 
compatible symptoms (12) and a laboratory confirmed diagnosis of cryptococcosis by one or 
more of: cytology, histopathology or a latex cryptococcal antigen agglutination test titer > 1:2 
from serum or cerebral spinal fluid.  Many cases were diagnosed without material for fungal 
culture.  Given that C. gattii was identified in virtually all previously reported cases of animal 
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cryptococcosis on Vancouver Island during the study period where culture material was 
available, confirmed and probable cases were included in the analysis (8, 11).   
 
Control animals were obtained from the veterinary clinic that diagnosed the case.  Controls were 
matched on species, age (within 1 year of case age) and dogs were size matched where large 
dogs were defined as > 20 kg and small dogs were < 20 kg.  Matching was used to control 
confounding by these variables and increase the power of the study as sample size was expected 
to be small.  Veterinary clinics were sent a letter outlining the control animals required and, 
beginning on a random day, asked any client presenting to the veterinary clinic whose animal 
met the control description if they would take part in the study.  If they refused, the next animal 
meeting the description was asked until all controls were obtained.  Exclusion criteria for control 
animals were those meeting the match requirements but presenting to the veterinary clinic with a 
diagnosis of, or clinical symptoms strongly suggestive of, cryptococcosis. 
4.2.2. Interview 
A standardized questionnaire was administered over the telephone or by personal interview for 
cases and over the telephone for all controls.  The questionnaire focused on two main areas; 
environmental variables and animal characteristics.  Controls were asked to answer the questions 
with reference to the same time period as the matched case.  The number of questions in the 
questionnaire was modified slightly between the two sampling periods as the investigation into 
C. gattii in the region identified other potential risk factors for infection. 
 
Environmental variables focused on factors that may increase exposure of the animal to the 
organism.  This included proximity to wooded areas or farmland, contact with eucalyptus trees or 
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products and owner activities six months prior to case diagnosis such as: hiking, gardening, 
chopping wood, handling birds/cleaning bird roosts or digging soil.  They were also asked about 
activities taking place within ten kilometers (km) of the animal’s primary residence in the six 
months preceding diagnosis that may disturb the environment such as construction, logging or 
commercial soil disturbance.   
 
Host characteristics explored included gender of the animal, travel on and off of Vancouver 
Island in the year preceding diagnosis, activity level, presence of potentially stressful changes or 
owner perceived stressors in the previous year, history of disease, medication, vaccination and 
owner supplementation with commercial products.  Animal-environment interactions including 
hunting and digging in soil were also included.  Owners were asked how much time their animal 
spent outside a 10 km radius of their home in a given week, how many hours were spent 
outdoors on a given day and how many years the animal had lived within the municipality. 
 
All questions were close ended.  Animal activity level was recorded on a four point scale (very 
low, low, high, very high) reflecting how active owners felt their pet was in certain 
environments.  Times spent outdoors, in the municipality and outside a radius of 10 km of the 
home were continuous variables; the remaining variables were dichotomous.   
4.2.3. Statistical analysis 
Odds ratios and 95% confidence intervals were calculated from McNemar chi-squared values for 
cases versus controls for each potential risk factor (13).  Continuous variables were evaluated 
using the paired t-test.  For animal activity level the four point response scale was converted to a 
dichotomous variable with very low and low activity classified as below average while high and 
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very high were classified as above average.  Data from both species were pooled together for the 
initial analysis and statistically significant risk factors were stratified by species for further 
evaluation. 
4.3. Results 
Over 80 owners of clinical cases were interviewed but only 17 matched controls in 2001/2002 
and 32 in 2003 were provided by the diagnosing veterinary clinic.  Less than 10 cases meeting 
the case description were not interviewed because the owner or diagnosing veterinarian was 
unwilling to participate in the study.  Based on available clinical information these cases did not 
differ from those included.  In total 49 cases and matched controls were included in the analysis.   
 
The results, pooled by species, are presented in table 1; only statistically significant risk factors 
and continuous variables are reported in the text.  Logging and soil disruption within a 10 km 
radius of the primary residence were the most significant risk factors for clinical cryptococcosis 
with those exposed being 14 (3.00, 65.37) and 18 (4.21, 76.93) times more likely to develop 
disease, respectively.  Animals that had traveled on Vancouver Island within the last year were 6 
(1.61, 22.33) times more likely to become infected than those without a travel history in the 
previous 12 months.  Likewise cases spent a mean of 2.2% of time outside of a 10 km radius of 
the primary residence while controls spent only 0.33%; a difference that was statistically 
significant (p=0.027).  Owners who went hiking or visited a botanical garden recently were 4 
(1.61, 9.90) and 5 (1.28, 19.60) times more likely to have animals become diseased.  Activity 
level of the animal was a significant risk factor as animals with owner classified activity level of 
above average in the house and outside unrestrained were 3 (1.02, 8.80) and 8 (1.40, 45.89) times 
more likely to become diseased, respectively. 
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 Owner administration of supplements increased the odds of disease 3.67 (1.11, 12.07) times.  
The odds ratio for owners knowing people with cryptococcosis or other people with animals 
diagnosed with cryptococcosis was 5.67 (1.91, 16.79).  Medication in the previous year and the 
presence of other pets were both considered protective in the crude analysis.  The amount of time 
an animal spent outdoors (p=0.498) or living in their current home municipality (p=0.703) were 
not significant. 
 
Results of stratification of the statistically significant risk factors by species are presented in 
table 4.2.  Logging and soil disturbance remained the greatest risk factors for disease.  Odds of 
disease in the presence of logging was increased 17 (2.12, 136.40) times in dogs and 6 (0.94, 
38.48) times in cats; however, only dogs remained statistically significant.  The measure of effect 
of soil disturbance was 17 (2.12, 136.40) and 20 (1.90, 52.76) for dogs and cats, respectively, 
and remained statistically significant for both species.  The odds of disease in dogs, but not in 
cats, was statistically increased when the animal had traveled on Vancouver Island in the 
previous 12 months.  Canine cases spent significantly more time outside a 10 km radius of their 
home compared to controls (p=0.024) but the difference was not statistically significant for feline 
cases (p=0.33).   
 
The odds of disease by species was similar to the pooled result for owners that hiked or visited a 
botanical garden in the previous six months, however only hiking of cat owners remained 
statistically significant.  When the variables reflecting animal activity level were stratified by 
species confidence intervals became large and none of the variables remained significant.  
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Supplements and knowing other cryptococcosis cases remained statistically significant risk 
factors for cats but not for dogs in the stratified analysis.  Medication in the previous 12 months 
remained significantly protective for dogs but not for cats, while the presence of other pets was 
not statistically significant for either species. 
4.4. Discussion 
Cryptococcus is a genus of environmental fungi that can be isolated from vegetative matter 
worldwide.  While the exact mode of infection is unknown it is widely accepted to be through 
inhalation of air-borne organism (14, 15).  Cryptococcus spp. have been isolated from the nasal 
passages of dogs, cats (16, 17) and koalas (18) in Australia and Canada without evidence of 
disease suggesting asymptomatic colonization of the nasal mucosa following environmental 
exposure.  It is not clear what triggers tissue invasion after colonization (1).   
 
Association with environmental sources of organism has been recognized as a primary risk factor 
for clinical cryptococcal disease in humans.  In Australia, the aboriginal population living in 
rural and semi-rural areas were over 12 times more likely to develop of C. gattii infection 
relative to the reference population (7).  This increased risk was proposed to be due to the 
populations close association with eucalyptus trees, a regional environmental reservoir.  Men in 
Australia and Papua New Guinea are also at an increased risk of infection with C. gattii, 
presumably because of increased contact with environmental organism (7, 19). 
 
Likewise in animals, environmental exposure to Cryptococcus spp. is an important risk factor.  
Male cats have been reported infected more often than females, with the suggestion that males 
are more likely to be exposed for behavioral reasons; however, other studies found no sex 
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predisposition (20-23).  In a retrospective study of 20 canine cryptococcosis cases in Australia, 
all dogs infected with C. gattii resided in rural or suburban environments suggesting increased 
proximity to the organism was a risk factor (24).  Doberman Pincers, Great Danes and other 
young, large breed dogs have been over represented relative to respective hospital populations 
for cryptococcosis cases suggesting a potential behavioral or genetic factor involved with 
infection (24, 25).  Unlike cats and humans, there is no evidence of sex predilection for 
cryptococcal infection in dogs (24).   
 
In this study, residing within 10 km of a site of commercial soil disruption or vegetation clearing 
were the most significant risk factors for clinical cryptococcosis due to C. gattii.  Physical 
disruption of the environment can result in more airborne particulate matter, including C. gattii 
(K. Bartlett, unpublished).  In contrast, owner induced vegetation and soil disruption at the 
residence, such as chopping wood, bringing wood into the house, digging soil, gardening or the 
exposure of animals to garden related products and home construction, were not identified as 
significant risk factors. This suggests such activities may not result in sufficient aerosolization of 
particulate matter to increase the risk of infection when compared to larger scale environmental 
disturbance associated with logging and commercial soil excavation.  Such findings imply a 
threshold level of air contamination exists that influences the risk of animal infection; or that the 
source of the infection is not in the immediate residential environment. 
 
Animals that had traveled on Vancouver Island within the last year were six times more likely to 
become ill than those with no travel history.  Clinical animals also spent a statistically greater 
percentage of time outside a 10 km radius of their primary residence than controls suggesting 
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they traveled more often.  Stratification of these variables revealed that this pooled result was 
influenced more by dogs than cats as dogs are more likely to travel with their owners.  Animals 
that travel may be at greater risk of disease because of increased opportunities for exposure.  
Environmental C. gattii has not been isolated ubiquitously on Vancouver Island (9) so travel 
would increase the probability of exposure to a positive site.  Duration of time spent in the 
residential municipality and time spent outdoors daily were not significant risk factors.  Similarly 
residing within two km of a wooded or agricultural area was not a risk factor.  This supports the 
hypothesis that some animals are not being exposed at their home; rather in places to which they 
travel where there is a higher environmental load.  Animals traveling off of Vancouver Island 
were not at increased risk of disease; however, C. gattii had not been isolated from the 
environment off of the island at the time of this study (26).   
 
Higher activity levels in the house and outdoors unrestrained were significant risk factors for 
disease; the odds of disease was also very high for animals outside and restrained; however, an 
extremely large confidence interval deemed the measure to not be significant statistically.  
Behavioral factors, including activity level, may significantly increase an animal’s risk of 
infection by bringing the individual in contact with C. gattii more frequently.  An active animal 
may also disturb the environment more and aerosolize additional organisms that can be inhaled.  
Gender, previously suggested to be a risk factor for cryptococcosis because of behavioral reasons 
was not determined to be significant in this case-control study. 
 
There was an increased risk of disease in animals whose owners hiked and visited a botanical 
garden in the six months preceding diagnosis.  As the environmental organism is small enough to 
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be transported on fomites it is possible that humans who participate in outdoor recreational 
activities transport the organism back to their residence and unwittingly expose their pet.  Dogs 
often accompany their owners on hiking trips and thus are at an increased risk of direct exposure 
through this recreational activity.  Stratification of hiking by species resulted in a wide and non-
significant confidence interval for dogs.   This is likely the result of a small sample size.  
Questions regarding visitation to botanical gardens were included to explore the role of imported 
vegetation, most specifically eucalypt trees, on disease.  None of the direct eucalyptus variables 
were significant and the risk of an owner visiting a botanical garden in the period prior to 
diagnosis may indirectly imply owner travel or affinity for gardening and naturalist activities. 
 
Owners who knew people with cryptococcosis or other people who had animals with 
cryptococcosis were over five times more likely to have a diseased pet themselves.  This result 
may be a result of recall bias as owners with a sick animal may be more likely to recall or seek 
out others with the same problem.  Alternatively the finding may reflect the clustering of positive 
environmental sites resulting in clustering of cases at the level of the neighborhood.  Owner 
administered supplements were a significant risk factor, but protopathic bias may have 
influenced this finding as the incubation period is long and, in the period preceding diagnosis, 
owners may have attempted to supplement an animal that appeared slightly unwell.  Likewise 
individuals who choose to supplement a sick pet may be more apt to bring the animal to the 
veterinarian in the case of illness or pay for diagnostic procedures that would facilitate 
identification of the case and inclusion in the study.   
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Medication in the year preceding diagnosis was identified to be protective; however this finding 
may have been influenced by Berkson’s bias, the selection of the control animals from a hospital 
population.  Control animals were those presenting to the veterinary clinic on a random day 
without a diagnosis of or clinical symptoms strongly suggestive of cryptococcosis.  Because the 
clinic was used as the control selection point animals were more likely than the general 
population to be presenting to the veterinarian because of illness and therefore be receiving 
medication.  Control selection could also have influenced the finding that owning multiple pets 
was considered protective when dogs and cats were pooled together.  Owners of multiple pets 
tend to visit the veterinary clinic more often and thus have greater odds of being selected as a 
control. 
 
Variables indicating potential immunosuppression including any history of disease, 
administration of steroids in the previous year, environmental changes or owner perceived 
stressors were not significantly associated with cryptococcosis cases.   The role of 
immunosuppression in feline cryptococcosis has been debated in the literature.  The prevalence 
of FIV in cats with cryptococcosis has been reportedly equivalent to that of a hospital population 
in Australia (22) while in the USA concurrent FIV or FeLV infection in cats with cryptococcosis 
was much higher that the general hospital population (21).  An examination of FIV positive and 
negative cats in the USA found C. neoformans more commonly in the oropharynx of FIV 
seropositive cats, although no cats had signs of clinical disease (27).  It is important to note that 
in many of these studies the causative agent has been identified as, or assumed to be C. 
neoformans and not C. gattii.  Clinical disease is dictated by host characteristics and the variety 
of infecting organism; C. neoformans var. neoformans and C. neoformans var. grubii are isolated 
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most commonly from immunosuppressed individuals (7, 28).  In contrast C. gattii should be 
considered a primary pathogen as it tends to infect immunocompetent hosts; even in areas where 
the organism is endemic C. gattii is rarely the cause of cryptococcosis in AIDS patients (7, 28, 
29).  This study lends further support that immunosuppression is not required for C. gattii 
infection.  
 
The first environmental isolation of C. gattii was from eucalyptus trees (Eucalyptus 
camaldulensis and E. tereticornis) in Australia (6, 30).  Subsequent to this discovery C. gattii has 
been recovered from material associated with eucalypt species in many other parts of the world 
including California, India and Brazil (31-34) along with non-eucalypt tree species from tropical 
and subtropical areas worldwide (31, 35-37).  There are studies that suggest alternative 
environmental sources of  C. gattii have yet to be identified, as molecular types isolated from 
clinical and environmental samples have been different in western and northern Australia (38-40) 
and clinical cryptococcosis caused by C. gattii has been reported from many regions where an 
environmental source has not been identified including parts of Australia, Africa and Papua New 
Guinea (38, 40-43).  In this study, animal association with eucalyptus trees or products was not a 
significant risk factor for cryptococcosis.  Cryptococcus gattii has been isolated from multiple 
tree species, soil samples and air samples on Vancouver Island, but never in association with a 
eucalypt tree (9).  This information suggests the existence of an alternative environmental niche 
for the organism on Vancouver Island. 
 
Cryptococcus neoformans has historically thought to be associated with avian excreta, 
particularly pigeons (32, 44-49).  Pet owners handling birds or cleaning up bird roosts was not 
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identified as a risk factor in this case-control study.  Given that avian excreta is rich in creatinine 
and other chemical constituents that promote fungal replication,  it is likely that the 
environmental niche of the fungus is soil or vegetation but that the organism is easily isolated 
from avian excreta as it provides a good media for growth (48, 50).   
 
Just over half of the requests for clinic matched controls were obliged.  The corresponding low 
sample size resulted in wide confidence intervals and results that, while biologically plausible, 
were occasionally not statistically significant.  Further stratification of potential risk factors to 
look for correlation between variables was not possible given the sample size restrictions.  
Regardless of this imposed limitation this study identified a dramatic increase in the odds of C. 
gattii in dogs and cats residing close to sites of major environmental disturbance, animals that 
travel on Vancouver Island and animals that are of above average activity level. 
 
It can be concluded that where an environmental organism is not uniformly and ubiquitously 
distributed in the environment, risk is increased if the organism is re-distributed through 
disruption of its environmental niche or the likelihood of encountering the environmental cluster 
is increased through travel or activity level.  Owners and veterinarians residing within an 
endemic area of environmental organism, such as C. gattii, should be aware of these risk factors 
such that risk can be mitigated or complete patient history data can facilitate prompt diagnosis.  
It is critical however that veterinarians discuss these risks in context as cryptococcosis remains a 
relatively rare disease of companion animals and the benefits of fresh air far exceed the risk of 
disease. 
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Table 4.1: Odds ratios and 95% confidence intervals for environmental and host variables 
Environmental variables n OR  95% CI 
Soil disturbance within 10 km of residence in previous 6 months 32 18 4.21, 76.93 
Logging with 10 km of residence in previous 6 months 32 14 3.00, 65.37 
Know other crypto case 32 5.67 1.91, 16.79 
Owners visiting a botanical garden in previous six months 32 5 1.28, 19.60 
Owners hiking in previous six months 32 4 1.61, 9.90 
Wooded area within 2 km of residence 49 2.67 0.75, 9.55 
Construction at residence 49 2.2 0.79, 6.16 
Contact with eucalypt trees 49 1.67 0.40, 6.87 
Animal contact with topsoil 47 1.5 0.62, 3.65 
Animal contact with compost 48 1.44 0.62, 3.36 
Animal contact with bark mulch 47 1.3 0.57, 2.96 
Animal contact with fertilizer 47 1.25 0.49, 3.16 
Farm within 2 km of residence 49 1.14 0.42, 3.15 
Wood products brought into residence 49 0.92 0.42, 2.02 
Owner chopping wood at residence 49 0.91 0.39, 2.14 
Contact with eucalypt cuttings 49 0.91 0.39, 2.14 
Contact with eucalypt products 49 0.86 0.29, 2.55 
Owner digging soil 49 0.71 0.32, 1.60 
Owners gardening at residence 49 0.6 0.15, 2.47 
Owner contact with birds 49 0.4 0.13, 1.23 
    
Host characteristics n OR  95% CI 
Activity outdoors (restrained) 11 10 0.95, 105.07 
Activity outdoors (unrestrained) 23 8 1.40, 45.89 
Travel on Vancouver Island in previous year 49 6 1.61, 22.33 
Travel off Vancouver Island in previous year 49 4 1.00, 16.75 
Owner administered supplements 32 3.67 1.11, 12.07 
Hunting 44 3 1.15, 7.86 
Activity indoors 28 3 1.02, 8.80 
Other stressors in previous year 32 2.67 0.75, 9.55 
Gender 49 1.56 0.68, 3.57 
Steroids in previous year 48 1.5 0.43, 5.27 
Digging in soil 47 1.18 0.53, 2.64 
Environmental changes in previous year 32 1 0.38, 2.66 
Vaccination in previous year 49 0.73 0.29, 1.80 
Any history of disease 49 0.6 0.26, 1.37 
Other pets in the household 49 0.36 0.13, 0.95 
Prescription medication in previous year 32 0.17 0.06, 0.49 
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  Canine   Feline     Pooled   
  n OR  95% CI n OR  95% CI n OR  95% CI 
Soil disturbance within 10 km 12 17 2.12, 136.40 20 20 1.90, 52.76 32 18 4.21, 76.93 
Logging with 10 km 12 17 2.12, 136.40 20 6 0.94, 38.48 32 14 3.00, 65.37 
Activity outdoors (unrestrained) 12 9 0.81, 99.95 11 4 0.53, 30.31 23 8 1.40, 45.89 
Animal travel on Vancouver Island 20 4.5 1.11, 18.19 29 7 0.55, 88.99 49 6 1.61, 22.33 
Know other crypto case 12 9 0.81, 99.95 20 4.33 1.37, 13.68 32 5.67 1.91, 16.79 
Owners visiting a botanical garden 12 5 0.33, 76.81 20 4 0.96, 16.75 32 5 1.28, 19.60 
Owners hiking in previous six months 12 4 0.96, 16.75 20 4 1.24, 12.88 32 4 1.61, 9.90 
Owner administered supplements 12 2 0.38, 10.56 20 7 1.16, 42.26 32 3.67 1.11, 12.07 
Hunting 17 5 0.33, 76.81 27 2.6 0.96, 7.02 44 3 1.15, 7.86 
Activity indoors 8 2 0.38, 10.56 20 4 0.96, 16.75 28 3 1.02, 8.80 
Other pets in the household 20 0.33 0.07, 1.53 29 0.38 0.11, 1.34 49 0.36 0.13, 0.95 
Prescription medication in previous year 12 0.05 0.01, 0.37 20 0.38 0.11, 1.34 32 0.17 0.06, 0.49 
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Table 4.2: Odds ratios and 95% confidence intervals for environmental and host variables stratified by species 
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5. Sub-clinical infection and asymptomatic carriage of 
Cryptococcus gattii in dogs and cats during an outbreak of 
cryptococcosis. 
 
5.1. Introduction 
Cryptococcosis is a fungal disease found worldwide in human and animal populations.    The 
epidemiology of clinical disease depends largely on the species of infecting organism.  
Cryptococcus neoformans var. grubii (serotype A) and C. neoformans var. neoformans (serotype 
D) are globally distributed and infect predominantly immunocompromised hosts (1).  
Cryptococcus gattii (serotypes B and C) has recently been recognized as a species distinct from 
C. neoformans based on molecular and mating type characteristics (2).  Clinical disease caused 
by C. gattii has not been associated with a suppressed immune system (3) and has historically 
been restricted to the tropics and sub-tropics, particularly in association with eucalyptus trees (4-
6).  The organism is not contagious and considered infectious only as a desiccated yeast cell or 
basidiospore as found in the environment (3).  Previously only C. neoformans has been routinely 
isolated from human or animal cases of cryptococcosis in Canada without a travel history to a 
region in which C. gattii is endemic. 
 
In 2001 an increased incidence of cryptococcosis was identified on southern Vancouver Island, 
British Columbia (BC), Canada.  Clinical disease was recognized in humans, dogs, cats, ferrets, 
porpoises, and llamas resulting in the first multi-species outbreak of cryptococcosis (7).  All 
animal and human isolates available for culture from BC were C. gattii serotype B.  Since 1999 
over 200 human and animal cases of cryptococcosis have been reported and the species list has 
been expanded to include birds and a horse (8).  Cases are clustered on the east coast of the 
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island within the Coastal Douglas-fir (CDF) biogeoclimatic zone.  Since 2001 C. gattii has been 
repeatedly and consistently isolated from soil, air and vegetation within the CDF zone (9). 
 
Infection in animals is thought to be the result of inhalation of the airborne environmental fungi 
and subsequent colonization of the nasal cavity and paranasal sinuses (6, 10-12).  In Australia it 
has been reported that dogs, cats (13) and koalas (14) can carry C. neoformans in their upper 
respiratory tract asymptomatically, suggesting that nasal colonization may be much more 
common than clinical disease. The following study was conducted to identify the prevalence, and 
outcomes, of sub-clinical cryptococcosis and asymptomatic carriage of C. gattii in the nasal 
passages of dogs and cats within the CDF zone of Vancouver Island, BC. 
5.2. Materials and Methods 
5.2.1. Study population 
Five veterinary clinics in four cities (figure 5.1) were selected as sampling sites based on 
caseload, identification of clinical cryptococcosis in their service area, location within the CDF 
region and willingness to participate.  At each clinic a fixed weekday was selected where the 
daily caseload included both medical and surgical appointments.  Owners presenting a dog or cat 
over six months of age to the veterinary clinic for reasons other than euthanasia or previously 
diagnosed clinical cryptococcosis were offered the opportunity to participate in the study.  
Owners completing a consent form and a brief information sheet could elect to have both a nasal 
swab and a blood sample collected or one of the two.  Sampling was carried out on average once 
every three weeks from June to December 2003. 
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5.2.2. Animal information 
Information collected from the owner included the animal’s age, sex, breed and the duration of 
time it had lived within the CDF zone on Vancouver Island.  Owners were asked if, in the last 
year, their pet had shown signs suggestive of respiratory tract disease including sneezing, 
coughing or nasal discharge, central nervous system disease including behavioral changes, 
seizures, poor coordination or balance problems, skin lumps or vision changes.  Owners were 
also asked to note other health problems observed in the last year that were not included on the 
list.  Finally owners rated how they perceived the overall health of their pet as one of very poor, 
poor, good or very good.  Reason for bringing the animal to the veterinarian and body weight of 
dogs was also recorded. 
5.2.3. Animal sampling 
Superficial nasal cultures were collected from unsedated animals.  In dogs a single Starplex 
StarSwab II (Starplex Scientific, Etobicoke, ON) moistened in transport media was inserted 0.5 
to 2 cm into both nasal vestibules and rotated on the mucosa.  In cats a similar procedure was 
conducted using a Calcium Alginate Fiber Tipped Ultrafine Aluminum Applicator swab (Calgi-
swab, Fisher Scientific, Toronto, ON) moistened with sterile saline (0.9% NaCl). The StarSwabs 
were placed in the associated transport media and the Calgi-swabs were placed in a 1.5 ml 
Eppendorf microcentrifuge tube (Brinkmann Instruments, Westbury, NY) containing ~0.2 cc 
sterile saline.  Animals undergoing general anesthesia for any procedure received a second, 
deeper nasal swab using a Calgi-swab.  The swab was rotated on the nasal mucosa of both nasal 
passages at approximately the level of the medial canthus of the eye.   
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Blood was collected using standard venipuncture technique.  A minimum of 1ml of blood was 
collected from each animal participating in the study, allowed to clot for 15-30 minutes at room 
temperature and centrifuged to separate the serum.   
5.2.4. Culture 
Culture swabs were plated onto Bird Seed Agar and incubated at 30 o C.  Plates were examined at 
48 hours, then daily for seven days.  Cryptococcus neoformans and C. gattii selectively use 
caffeic acid in the medium to produce melanin, resulting in brown colonies.  Suspect colonies 
were transferred to Malt Extract Agar (MEA) and Canavanine-glycine-bromothymol blue (CGB) 
agar.  Cryptococcus gattii turns the CGB agar cobalt blue while C. neoformans remain negative.  
Colonies growing on MEA were serotyped using capsular antibodies (Crypto-check, Iatron 
Laboratories, Japan).  Biochemical identification was achieved using API 20 AUX strips 
(bioMérieux, St. Laurent, Quebec). 
5.2.5. Antigen test 
Samples were treated with pronase (15) prior to the use of a latex cryptococcal antigen 
agglutination test for the measurement of cryptococcal antigen in the sera (Cryptococcal Antigen 
Latex Agglutination System (CALAS); Meridian Bioscience, Inc., Cincinnati, Ohio).  The 
CALAS test cannot identify the organism beyond the level of the genus.  Animals with a titer ≥ 
1:2 were considered positively infected with Cryptococcus spp. (16).   
5.2.6. Statistical analysis 
When C. gattii was isolated from either the deep or superficial swab the animal was considered 
positive on nasal culture.  Animals testing positive on either a nasal culture or antigen test were 
given an overall rating of positive for Cryptococcus spp.  Results were stratified by species.  The 
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owner-evaluated overall health rating was converted to a dichotomous variable where scores of 
very poor and poor were combined to below average; good and very good were combined to 
above average.  Dogs were classified into two size categories based on body weight above or 
below 15 kilograms. 
 
Descriptive and comparative statistics were computed using SPSS 12.0 (SPSS Inc., Chicago, Il., 
USA).  Odds ratios and 95% confidence intervals were used to evaluate the association between 
positive test results and animals presenting to the clinic for illness compared to routine 
procedures, owner perceived health status, sex, and health problems in the previous year.  The 
Kolmogorov-Smirnov Z test was used to evaluate the normality of the distribution of continuous 
variables including age and duration of residence within the CDF zone.  For variables with 
normal distribution mean values were reported and the T-test was used to compare means 
between positive and negative animals.  Where the results of the Kolmogorov-Smirnov Z test 
were significant at the 5% level median values were reported and the Mann-Whitney U (MWU) 
test was used to compare means between positive and negative animals.  The relative proportions 
of infected species were compared using odds ratios and 95% confidence intervals.  The 
prevalence of positive animals in the four sampling cities was compared using a Chi-Square test.  
Kappa statistics were calculated to determine the agreement between the two nasal swabs and 
between the antigen test and nasal culture.  
5.2.7. Follow-up testing 
Owners of positive animals identified as sub-clinically infected with Cryptococcus spp. or 
carrying C. gattii in their nasal passages were asked to bring their animal to the veterinarian for 
follow-up testing as often as possible to a maximum of once a month.  Follow-up testing was 
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available until October 2004.  At each follow-up visit a serum sample and superficial nasal swab 
was collected for CALAS testing and fungal culture.  Serial 10 fold dilutions were carried out on 
serum samples; when higher dilutions showed agglutination and dilutions were large, 
intermediate twofold dilutions were run in an attempt to more accurately determine an endpoint.  
5.3. Results 
5.3.1. Initial testing 
Of serum samples collected from 84 cats, six (7.1%) had an antigen titer ≥ 1:2 (Table 5.1).  
Titers ranged from 1:2 to 1:200.  Superficial nasal cultures of 94 cats identified three (3.2%) 
animals with C. gattii serotype B in the nasal vestibule while deep nasal swabs from 13 cats 
under general anesthesia identified two (15.4%) animals with C. gattii serotype B in their nasal 
cavity.  Overall 7 (7.4%) cats tested positive on one or more tests.  One of the seven cats resided 
in the Parksville area, five in Nanaimo and one in Duncan but the proportion of cats positive on 
one or more tests was not statistically different between cities (p=0.122). 
 
The mean age of cats testing positive on one or more test was 8 years (SD 7.0 years, range 0.7-18 
years) and was not significantly different from cats who were not positive on any test performed 
(T-test, p=0.54).  The median time positive cats had resided in the CDF zone of Vancouver 
Island was 5.0 years (range 0.5-18 years) which was not statistically different from the negative 
cats (median 4.8, range 0.5-16, MWU p=0.44).   
 
The odds of being positive on one or more test were not statistically different for male cats 
relative to females (OR 1.27, 95% CI 0.27, 6.03).  The odds of a positive test result was 3.33 
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(95% CI 0.320, 34.71) times greater in cats with an owner perceived health status of poor 
relative to good, however, this result was not statistically significant.  The odds of a positive test 
result was increased in cats with a history of respiratory signs (OR 1.46, 95% CI 0.16, 13.56), 
central nervous system symptoms (OR 2.13, 95% CI 0.22, 20.49), skin lumps (OR 2.28, 95% CI 
0.24, 22.13) and vision changes (OR 5.50, 95% CI 0.45, 67.49) in the last year relative to those 
without these symptoms; however, none of these results were statistically significant.  The 
presence of other health problems in the previous 12 months was slightly protective (OR 0.68, 
95% CI 0.08, 5.858) but this result was not statistically different compared to cats without other 
health problems.  Cats testing positive on one or both tests for Cryptococcus spp. were less likely 
to have presented to the veterinarian for  owner perceived illness verses routine veterinary 
procedures (OR 0.15, 95% CI 0.02, 1.32); however, this result was not statistically significant.  
The breed distribution of the positive cats consisted of five domestic shorthairs, one domestic 
longhair and one Himalayan. 
 
Two of 266 (0.8%) dogs had an antigen titer of 1:2 (Table 5.1).  Of 280 superficial nasal cultures 
C. gattii serotype B was isolated from three (1.1%) dogs.  Cryptococcus gattii was not isolated 
from any of the 34 dogs from which a deep nasal swab was collected.  Overall five (1.7%) dogs 
tested positive on one of the tests, no dogs were considered positive on more than one test.  Four 
of the five dogs positive on any of the tests were from the Duncan area and the remaining 
positive dog was in Parksville.  This difference in the prevalence of positive dogs by city was 
statistically significant (p=0.03). 
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The median age of dogs positive on either test was 6.6 years (range 3.4-11.6 years) which did not 
differ statistically from the remainder of the dogs tested (median 5.8, range 0.5-16.5, MWU 
p=0.46).  Positive dogs had resided in the CDF zone for a median of 5 years (range 3.4-10 years) 
which was not statistically different from the negative dogs (median 4.0, range 0.5-16.0, MWU 
p=0.51).  The odds of a positive test was not statistically different for males relative to females 
(OR 0.89, 95% CI 0.15, 5.42).  The odds of a positive test result was 3.99 (95% CI 0.44, 36.01) 
times greater in dogs with an owner perceived health status of poor relative to good, however, 
this result was not statistically significant.  The odds of a positive test result was increased in 
dogs with a history of respiratory signs (OR 4.09, 95% CI 0.43, 38.79), central nervous system 
symptoms (OR 1.78, 95% CI 0.21, 15.38), skin lumps (OR 1.41, 95% CI 0.15, 12.88), vision 
problems (OR 3.17, 95% CI 0.36, 28.13) and other health problems (OR 2.37, 95% CI 0.39, 
14.52) but these results were not statistically significant.  The odds of dogs presenting to the 
veterinarian for owner perceived illness being positive for Cryptococcus spp. in was 3.17 (95% 
CI 0.35, 28.72) times that of animals brought to the clinic for routine veterinary procedures.  Dog 
breeds that tested positive included two Labrador Retriever crosses, one German Shepherd, one 
Jack Russell Terrier and one Toy Poodle.  There was no significant difference in the proportion 
of dogs testing positive above and below 15 kilograms (OR 1.46, 95% CI 0.24, 8.92). 
 
Cats were 10.15 times (95% CI OR 2.01, 51.31) more likely to be positive on the antigen test 
than dogs.  Combination of the superficial and deep nasal culture results into a single 
dichotomous variable of positive or negative on culture revealed that cats were 4.10 (95% CI 
0.90, 18.68) times more likely than dogs to carry C. gattii in their nasal cavity, however this 
result was not statistically significant at the 5% level.  When the results of the antigen test and 
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nasal cultures were combined into a single positive or negative variable the difference between 
species was significant with cats being 4.42 times (95% CI 1.37, 14.28) more likely than dogs to 
be positive on one or both tests. 
 
Three of 12 (25%) positive animals were positive on both the antigen test and nasal culture.  
Four of 12 (33%) of animals had a positive nasal culture but negative antigen test and 5 of 12 
(42%) were positive on antigen test alone.  A computed kappa of 0.39 (95% CI 0.28, 0.49) 
suggests only fair agreement between the serum antigen test and nasal culture.  Forty-seven 
animals had both deep and superficial swabs of which 44 were negative on both cultures, one 
was positive on both cultures and one animal was positive on each of the deep and superficial 
cultures.  The kappa statistic of 0.48 (95% CI 0.19, 0.76) suggests moderate agreement between 
the two swab techniques.   
5.3.2. Follow-up testing 
Twelve animals positive on initial testing had between one and four follow-up samples collected; 
the results for each individual animal are shown in table 5.2.  Animals 1-7 are cats and 8-12 are 
dogs.  Of the seven cats, six had a titer on one or more test dates; five of the seven had the 
organism isolated from their nasal cavity.  One cat (#6) had the organism isolated from its nasal 
cavity on two of four occasions but never had a positive titer.  Two cats (#’s 5 & 7) had positive 
titers on multiple occasions but the organism was never isolated from their nasal cavities.  Four 
cats (#’s 1, 2, 3 & 4) had both a positive titer and organism in their nasal cavities on one or more 
occasions.  Titers in cats ranged from 1:2 to 1:2500. 
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Two cats (#’s 1 & 2) progressed to clinical disease.  Case 1 was a 19 year old, spayed female 
domestic shorthair cat presented initially to the veterinary clinic for illness.  Upon initial 
examination the owners reported their cat to be in poor overall health with severe arthritis and 
regular constipation.  In the previous year the owner noted that the cat had a chronic sneeze.  The 
cat had lived on Vancouver Island all of its life.  In February 2004 the cat showed central 
nervous symptoms including ataxia and seizures and was humanely euthanized. 
 
Case 2 was a 15 year old, neutered male domestic shorthair cat presented to the veterinarian for 
annual vaccination.  Upon entry into the study the owners reported the cats overall health to be 
very good and noted that in the previous year the cat had no symptoms suggestive of 
cryptococcosis.  The cat had lived on Vancouver Island all of his life.  Upon initial examination 
the cat was deemed healthy and received vaccination; although the owners reported regular 
sneezing.  In late November 2003 the cat showed symptoms of respiratory tract infection 
including nasal discharge and sneezing and was started on antifungal therapy in December 2003.  
Ten months after initiation of therapy the CALAS titer was negative. 
 
Of the five dogs, two had a positive titer at one or more test dates, four of the five had organism 
isolated from their nasal cavity.  Three dogs (#’s 10, 11 & 12) had the organism isolated from 
their nose on initial testing but never on subsequent tests.  One dog (#8) had a single positive 
antigen titer and organism isolated from its nasal cavity on a single occasion, but not on the same 
date.  One dog (#9) had a titer of 1:2 on initial testing but all subsequent CALAS tests were 
negative and C. gattii was never isolated from its nasal passages.  A CALAS result of 1:2 was 
the only titer detected in dogs. 
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5.4. Discussion 
Identification of sub-clinical infection and nasal colonization of dogs and cats with Cryptococcus 
spp. is an important step in the characterization of the outbreak of clinical cryptococcosis on 
Vancouver Island.  Of animals sampled within the CDF zone of Vancouver Island 7.4% of cats 
and 1.7% of dogs has either a positive nasal culture or antigen titer indicating that they were 
colonized by or infected with Cryptococcus spp.   
 
On physical examination none of the animals identified as positive on either test showed signs 
consistent with cryptococcal disease.  The most common presentations of feline and canine 
cryptococcosis include respiratory, central nervous system, dermal or ocular symptoms (17-19).   
Owners of positive dogs and cats reported a slightly increased prevalence of symptoms 
suggestive of cryptococcosis within the previous 12 months, however these results were not 
statistically significant.  The odds of an animal testing positive was increased in animals 
considered to be in below average health by their owners, however, this result was not 
statistically significant and positive animals were equally likely to have presented to the 
veterinarian for routine procedures as for owner-perceived illness.   
 
Cryptococcus gattii serotype B was isolated from 4.2% and 1.1% of cats and dogs, respectively.  
Although superficial nasal swabs were assumed to confer good agreement with a nasal flush in 
koalas (14) numerical results were not reported and extrapolation of this assumption across 
species should be made with caution.  In this study there was a wide confidence interval with 
only moderate agreement between the two swab techniques.  The lack of pattern in the disparity 
between deep and superficial swabs suggests that both samples may underestimate true nasal 
 80
colonization.  Correspondingly there was only fair agreement between the antigen test and nasal 
culture.  The kappa statistic is highly dependent on the true prevalence of disease in the 
population and where prevalence approaches one or zero kappa is sharply reduced (20).  Further 
studies on a cohort of animals with a higher prevalence of colonization and infection are required 
to evaluate test agreement more meaningfully.   
 
Of the animals positive on one or more tests 33% had a positive nasal culture without a positive 
antigen titer.  Studies of presumed healthy animals in Australia recovered C. neoformans and C. 
gattii from cats, dogs (13) and koalas (14, 21).  Based on the lack of cryptococcal antigen or 
pathology of the nasal cavity these studies concluded that Cryptococcus spp. can colonize the 
nasal passage of animals without an associated local or systemic infection.  In contrast 25% of 
animals tested in BC that had C. gattii in their nasal cavities also had antigen in their serum 
suggesting sub-clinical infection versus nasal colonization.  Forty-two percent of animals 
positive on any test had an antigen titer without a positive nasal culture.  The CALAS test has 
been reported to have high specificity in diseased cats and dogs (22, 23) making false positive 
reactions unlikely; however, effectiveness of the CALAS test in asymptomatic animals has not 
been evaluated.  Furthermore, the sensitivity of nasal culture in colonized animals is unknown 
and it is possible that the organism was missed during the nasal swab or that the source of 
antigen was not in the nasal passage. 
 
Overall cats had significantly greater odds of testing positive on either culture or antigen test or 
antigen test alone when compared to dogs.  Cats had increased odds of carrying C. gattii in their 
nasal cavity but this result was not statistically significant.  Given the low number of positive test 
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results this study may lack the power necessary to identify a statistical difference.  
Cryptococcosis is the most common systemic mycoses of cats (19) and clinical disease has been 
reported with equal or greater frequency in cats than in dogs (18).  Likewise, on Vancouver 
Island the reported number of clinical cases in cats outweigh that of dogs (8).   
 
Previously published studies on risk factors for animal cryptococcosis focus only on clinical 
cases.  Cryptococcal disease has been reportedly been more common in young large dogs (12, 
24) and male cats (10, 25, 26), potentially for behavioral reasons.  This study failed to identify 
sex, age or size of dog as statistically significant factors for asymptomatic infection or 
colonization by the organism.  Elsewhere environmental exposure to infectious organism is 
considered a risk factor for cryptococcal disease (12, 27).  While C. gattii has only been 
identified within the CDF zone on Vancouver Island (9) the duration of time dogs and cats lived 
within the region was not a risk factor for asymptomatic infection or colonization.  Previously 
reported risk factors may be restricted to animals that become clinically ill and not apply to 
asymptomatic or otherwise healthy animals.  Subsequent investigations into risk factors for 
asymptomatic infections should include a larger sample size to increase the study power.  
Because the distribution of cat and dog breeds within the study population is unknown the effect 
of breed cannot be evaluated.  
 
All of the sampling clinics lie within the CDF zone but the highest proportions of positive 
animals were in Duncan and Nanaimo which are located in the center of the testing area.  It is 
interesting to note that no animals tested positive in Victoria which lies on the southern most 
extreme of the CDF zone.  In Australia koalas have been used to successfully identify geographic 
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areas with a high-grade presence of C. gattii in the environment (21).  Further sampling of dogs 
and cats at the edge of the CDF zone in combination with environmental testing may identify 
companion animals as a similar sentinel.  
 
Follow-up testing of positive animals revealed that dogs and cats can clear the organism, remain 
sub-clinically infected or progress to overt disease.  Cryptococcus gattii was initially isolated 
from the nasal cavity of three dogs without antigenemia; however the organism was never 
recognized on subsequent testing.  A single cat had C. gattii isolated from the nasal cavity on 
two of four visits while cryptococcal antigen was never found in its serum.  These results suggest 
the nasal passages of animals residing within a region where environmental C. gattii is present, 
may be transiently colonized by the organism without rapid progression to infection.  Failure to 
re-isolate the organism from any of the dogs suggests that the presence of the organism in the 
nose is relatively brief; or that the swab technique is not sufficient to capture the organism at 
each sampling interval.  Cryptococcus gattii was isolated twice from the cat suggesting better 
recovery of the swab, more persistent colonization or re-exposure of the animal to airborne fungi.    
As the CALAS test detects only circulating antigen, extension of infection beyond the nasal 
mucosa is required before the test can be positive.  Factors mediating progression from 
colonization to infection eliciting antigenemia are unknown although dose response, concurrent 
disease or other forms of immunosuppression have been suggested (3, 21).  
 
One dog had an antigen titer of 1:2 on initial testing but not on any follow-up visits, 
Cryptococcus spp. was never isolated from its nose.  Two cats had positive titers on more than 
one occasion but the organism was never isolated from the nasal cavity.  The sensitivity of 
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superficial nasal culture in animals is unknown and it is possible that the organism was missed 
during the nasal swab, or that the source of antigen was not in the nasal passage.  As the 
effectiveness of the CALAS test has not been evaluated in asymptomatic animals false positive 
results cannot be ruled out.  One dog had a low titer with no culture on initial testing; on follow-
up examination C. gattii was isolated from the nasal passage but the CALAS test was negative, 
disparities potentially elicited by the aforementioned limitations of the diagnostic tests.  These 
four animals with antigenemia on one or more occasion were all CALAS negative at the end of 
the study, between five and 11 months after the date of the last positive CALAS test.  These 
results suggest that the animals may have cleared the infection.  Demonstration of cryptococcal 
antigen in serum or cerebral spinal fluid implies infection with the organism and a titer of 1:2 has 
been reported to be clinically relevant in cats (16).  Asymptomatic infection has been proposed to 
be a self limiting condition in koalas but individuals with low positive titers may harbor foci of 
infection that could reactivate (21).  
 
Four cats had both antigenemia and C. gattii in their nasal cavity; two of these progressed to 
clinical disease.  Both animals had antigen titers greater than other cats in the study and titer 
values increased over the sampling period.  The highest titer observed in a cat not showing 
clinical signs was 1:32.  In a cohort study of koalas in Australia all clinical animals documented 
in the study had antigen titers ≥ 1:128 and an increased incidence of nasal colonization; while 
animals without clinical symptoms had titers ≤ 1:64 (21).  The results of this small study suggest 
that asymptomatic animals with a titer equal to or less than 1:32 clear the infection while those 
with a higher titer go on to become diseased.  Further investigation into the relationship between 
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asymptomatic colonization and clinical disease is warranted as clinical cases in BC have been 
diagnosed with titers as low as 1:2 (23).   
 
The findings of this study demonstrate the need for a better understanding of sub-clinical 
infection and nasal colonization of C. gattii in companion animals.  In areas of Australia where 
environmental exposure of koalas to C. gattii is high, sub-clinical infection is relatively common 
while progression to clinical disease is rare (21).  Given the recent emergence of the organism in 
southwestern BC more information on environmental load, variables influencing exposure and 
risk factors for progression from colonization to clinical disease is warranted.   
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Table 5.1: Positive animals and odds ratios for cats relative to dogs tested on Vancouver Island, 
BC, Canada 
  Feline Canine OR 95% CI 
Any test  7/95 5/283 4.42 1.37, 14.28 
CALAS  6/84 2/266 10.15 2.01, 51.31 
Total culture  4/94 3/280 4.10 0.90, 18.68 
     Superficial 3/94 3/280 - - 
     Deep 2/13 0/34 - - 
CALAS: Cryptococcal Antigen Latex Agglutination System 
 86
87
Table 5.2: CALAS titer and results of nasal C. gattii culture on follow-up testing 
    Animal ID                       
Date Test 1* 2† 3 4 5 6 7 8 9 10 11 12 
Aug-03 CALAS  1:200  1:64  1:2 NT NT NT NT NT NT NT NT NT 
 Culture pos pos pos NT NT NT NT NT NT NT NT NT 
Sep-03 CALAS  1:2  1:50 NT  1:2 NT NT NT  1:2  1:2 0 0 NT 
 Culture pos pos NT pos NT NT NT neg neg pos pos NT 
Oct-03 CALAS  1:200 NT 0 NT NT NT NT 0 0 0 NT 0 
 Culture pos NT neg NT NT NT NT pos neg neg NT pos 
Nov-03 CALAS  1:2500  1:1024  1:16 NT  1:32 0 NT NT NT NT 0 0 
 Culture NT neg neg NT neg pos NT NT NT NT neg neg 
Dec-03 CALAS  1:2500  1:500  1:2 NT  1:2 0  1:2 0 0 0 0 NT 
 Culture pos pos neg NT neg pos neg neg neg neg neg NT 
Jan-04 CALAS NT  NT  1:2 NT NT  1:2 NT NT NT NT NT 
 Culture NT  NT pos NT NT neg NT NT NT NT NT 
Feb-04 CALAS   NT NT NT NT NT NT NT NT NT NT 
 Culture   NT NT NT NT NT NT NT NT NT NT 
Mar-04 CALAS   NT NT NT NT NT NT NT NT NT NT 
 Culture   NT NT NT NT NT NT NT NT NT NT 
Apr-04 CALAS   NT NT  1:2 0  1:2 NT NT NT NT NT 
 Culture   NT NT NT neg NT NT NT NT NT NT 
May-04 CALAS   NT NT NT NT NT NT NT NT NT NT 
 Culture   NT NT NT NT NT NT NT NT NT NT 
Jun-04 CALAS   NT NT NT NT NT NT NT NT NT NT 
 Culture   NT NT NT NT NT NT NT NT NT NT 
Jul-04 CALAS   NT NT NT NT NT NT NT NT NT NT 
 Culture   NT NT NT NT NT NT NT NT NT NT 
Aug-04 CALAS   0 NT NT NT NT 0 0 0 0 NT 
 Culture   neg NT NT NT NT neg neg neg neg NT 
Sep-04 CALAS   NT NT NT 0 NT NT NT NT NT NT 
 Culture   NT NT NT neg NT NT NT NT NT NT 
Oct-04 CALAS   NT NT 0 NT 0 NT NT NT NT NT 
  Culture     NT NT neg NT neg NT NT NT NT NT 
NT = not tested, neg = negative              
* died February 2004             
† began antifungal therapy December 2003           
 
Figure 5.1: Location of sampling clinics (clear circles) and distribution of the Coastal 
Douglas Fir Biogeoclimatic zone on Vancouver Island, BC, Canada. 
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6. Cryptococcus gattii in horses and wildlife of 
Vancouver Island, British Columbia, Canada 
6.1. Introduction 
Since 1999, Cryptococcus gattii, a species now distinct from C. neoformans (1), has 
emerged as an important pathogen of humans and animals in southwestern British 
Columbia (BC) (2-5).  Previously only C. neoformans had been isolated from animals or 
humans in Canada and C. gattii was thought to be restricted to the tropics and sub tropics 
(6, 7).  Clinical illness has been identified in humans and numerous animal species in BC 
including cats, dogs, ferrets, llamas, porpoises, domestic birds and a horse.  Cases to date 
have been clustered on the east coast of Vancouver Island; largely within the coastal 
Douglas fir (CDF) biogeoclimatic zone (8).  Cryptococcus gattii has been routinely 
isolated from soil, air and vegetation within the CDF zone since 2001 (4, 9).   
 
Given the airborne nature of this organism, it may be assumed that many species residing 
within endemic areas are exposed, but infection has been largely unnoticed.  
Asymptomatic carriage of C. gattii has been recognized in companion animal species of 
BC; presumably as a result of contact with airborne infectious material (8, 9).  
Environmental exposure and asymptomatic colonization of the respiratory tract has been 
proposed to be much more common than clinical disease (10, 11), however, variables 
influencing the initiation of infection remain unclear.  The prevalence of exposure of 
humans and animals in BC is unknown.   
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The objective of this study was to identify terrestrial mammalian wildlife species and 
horses that have been exposed to or infected with C. gattii on Vancouver Island, BC.  
Horses were selected because, on Vancouver Island, they are housed predominantly 
outdoors, are dispersed throughout the endemic area, are susceptible to the organism and 
public concerns regarding equine cryptococcosis facilitates sampling.  Wild mammal 
species were targeted because samples were accessible and the majority of domestic 
cases on Vancouver Island were mammals.    
6.2. Materials and Methods 
6.2.1. Wildlife sampling 
Between February and August 2004, a deep swab of the nasal mucosa using a Starplex 
StarSwab II (Starplex Scientific, Etobicoke, ON) and lung tissue, where possible, were 
collected for fungal culture.  Sources of live and dead animals included wildlife 
rehabilitation facilities, veterinarians, biologists and registered trappers.  Any mammalian 
species live-trapped or killed and known to reside in the CDF zone on Vancouver Island 
between January 1999 and August 2004 were eligible for inclusion in the study.  Species 
and approximate life stage were recorded along with the location of animal capture when 
available.     
6.2.2. Equine sampling 
All BC veterinary medicine association (BCVMA) registered veterinary clinics servicing 
equine clients within the region where clinical cryptococcosis cases had been identified 
were contacted for participation.  Veterinarians were given maps of their service area that 
included sites where C. gattii had been isolated from the environment (Bartlett, 
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unpublished) and an associated 10 km zone around the positive sample locations.  
Practitioners were asked to provide names of equine clients residing within the 10 km 
zone that would be interested in participating in the study.   
 
Between July 24 and August 9, 2004 samples were collected from horses residing in 
identified buffer zones.  Material collected included a swab of the nasal mucosa using 
StarSwab II (Starplex Scientific, Etobicoke, ON) moistened in transport media, inserted 
10-15 cm into both nasal vestibules and rotated on the mucosa.  A minimum of 5 ml of 
blood was collected from each animal participating in the study using standard 
venipuncture technique.  Blood was allowed to clot for a minimum of 30 minutes and 
centrifuged to separate the serum.   
 
Data collected on each horse tested included age, breed, underlying health problems, 
duration lived at sampling location and on Vancouver Island, average time spent outside 
per 24 hour period, source of hay and if hay was fed on the ground or in a feeder.  The 
difference in age, duration of residence on current property and Vancouver Island 
between positive and negative horses was evaluated using the Mann-Whitney U test.  The 
relative number of horses fed on or off of the ground, local or imported hay and housed 
outdoors or both in and out were compared using the Fishers exact test. 
6.2.3. Laboratory analysis 
Culture swabs were plated onto Bird Seed Agar and incubated at 30 o C for 48 hr.  Plates 
were checked for growth daily for ten days before being regarded as negative.  Colonies 
conforming to cryptococcal morphology were identified and serotyped using 
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agglutinating antibodies (Crypto-check, Iatron Laboratories, Tokyo, Japan).  Lung tissue 
was splayed on a sterile surface and dissected to allow access to the interior surface using 
a scalpel blade sterilized by alcohol dip and flaming.  Internal and external surfaces were 
swabbed using a cotton-tipped applicator (Puritan, Fisher Scientific).  The applicator was 
rolled across a differential agar (Bird Seed Agar) and a rich nutrient agar (Saboraud 
Dextrose Agar, BBL).  Agar plates were incubated and checked for growth as above. 
 
Serum samples were treated with pronase (12) prior to the use of a latex cryptococcal 
antigen agglutination test for the measurement of cryptococcal antigen in the sera 
(Cryptococcal Antigen Latex Agglutination System (CALAS); Meridian Bioscience, Inc., 
Cincinnati, Ohio).  The CALAS test cannot identify the organism beyond the level of the 
genus.  Animals with a titer ≥ 1:2 were considered positively infected with Cryptococcus 
spp.   
6.3. Results 
6.3.1. Wildlife sampling 
Nasal swabs were collected from 91 individuals representing 14 species; 19 living harbor 
seals (Phoca vitulina) and 72 post-mortem samples.  A list of all species, the respective 
number of isolates and age categories of animals sampled are presented in table 6.1.  
Lung tissue was available for culture from 68 animals representing 13 species.  
Cryptococcus gattii was isolated from the nasal swab of two Eastern Grey Squirrels 
(Sciurus carolinensis) trapped at the same location in the city of Duncan, BC.  Lung 
tissue was available from one of these squirrels and fungal culture of the tissue yielded no 
Cryptococcus spp.  
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6.3.1. Equine sampling 
Nasal swabs and serum samples were collected from 260 horses residing within 10 km of 
a site where C. gattii had been isolated from the environment.  No horses were positive 
on the antigen test, but the organism was isolated from the nasal passages of four horses.  
All positive horses resided in the area of Duncan, BC with one horse directly adjacent to 
the trapping site of the two positive squirrels. 
 
All horses, except for one, had lived on Vancouver Island their entire lives.  This horse 
had moved to the island approximately six months prior to testing and resided only in the 
Duncan area during that time.  The median duration of residence on Vancouver Island 
was 5 years (minimum 3 months, maximum 9 years) for the positive horses and 8 years 
(minimum 3 months, maximum 32 years) for the negative horses; a difference that was 
not statistically significant (p=0.198).  The median duration of positive horses living on 
the property where testing occurred (2.25 years, minimum 3 months, maximum 6 years) 
did not differ significantly from that of negative horses (3 years, minimum 3 months, 
maximum 23 years).  The four positive horses were 4, 6, 9 and 10 years of age; the 
median age of positive horses (7.5 years) did not differ significantly from that of horses 
without organism in their nose (12 years, minimum 3 months, maximum 35 years, 
p=0.202).  The proportion of positive horses fed on the ground did not differ statistically 
from the negative horses (p=0.264).  None of the positive horses had any owner reported 
illness or historical medical problems. 
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6.4. Discussion 
Recent investigation into subclinical infection in companion animals identified 4.3% of 
cats and 1.1% of dogs residing within the CDF zone of Vancouver Island had C. gattii in 
their nasal cavity (8).  The organism was present on 1.5% of nasal swabs collected from 
horses and 2.2% of swabs collected from wild mammals in this study.  Identification of 
C. gattii in the nasal passages of animals is likely the result of environmental exposure.  
Lung tissue was available from one of the positive squirrels but the organism was not 
isolated.   Cryptococcal antigen was not identified in serum samples collected from any 
of the four horses suggesting nasal colonization and not systemic infection.  Both grey 
squirrels were trapped and humanely euthanized on private property as the species is 
considered an invasive alien in this area; both were presumed to be healthy.  On gross 
post-mortem examination no lesions were observed suggestive of clinical cryptococcosis 
or other diseases.  Failure to identify pathology or systemic infection in an individual 
suggests nasal colonization resulting from environmental exposure and not clinical 
infection.  Without isolation of the organism from a normally sterile site, histological 
examination of tissue from the nasal cavity, or serum upon which to run a cryptococcal 
antigen test, it is difficult to make inferences on the status of the organism within the 
respiratory tract; however it appears that the squirrels were colonized by and not infected 
with the organism as per the horses.   
 
Both positive squirrels and all four horses were from the same geographic location.  The 
city of Duncan is central in the region in which clinical cryptococcosis cases have been 
reported (13) and a cross-sectional study in dogs and cats identified Duncan to have a 
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higher proportion of colonized or sub-clinically infected animals (8).   Environmental C. 
gattii has not been isolated ubiquitously on Vancouver Island (4) and investigation into 
environmental C. gattii identified increased concentration of organism in soil samples 
collected from the Duncan area relative to most other parts of Vancouver Island (Bartlett, 
unpublished).   
 
As the two squirrels were the only wildlife species submitted from this region it is 
difficult to draw conclusions regarding the relative role of location compared to species 
of wildlife.  The remaining negative squirrels were submitted from Victoria (n=13) and 
Salt Spring Island (n=1).  Further investigation into nasal colonization of wildlife species 
within a region where the environmental organism has been quantified is an important 
step in the understanding of the prevalence of the organism in wild populations.  In 
Australia it has been proposed that heavily colonized or infected koalas may contaminate 
previously culture negative vegetation (14).  Eastern Grey Squirrels were introduced to 
Vancouver Island in the Victoria area; their northward expansion may facilitate 
transmission of C. gattii to regions currently free from of the organism.  
 
Over 74% of wild mammals sampled in this study were collected from wildlife 
rehabilitation facilities.  While younger animals are often over represented, this sampling 
technique is an inexpensive way to collect samples from multiple species in a short 
period of time.  It is important however, to consider the effect of a young sample 
population on the results; younger animals will have had a shorter duration of exposure 
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and, given the long incubation period of Cryptococcus spp., younger animals may not 
manifest signs of clinical disease at the time of sampling.   
 
Failure to culture the organism from the nasal cavity of any living wildlife may be 
influenced by the inability to sample with the same intensity; swabs collected from living 
animals were more superficial than those collected post-mortem.  Cryptococcus gattii has 
been repeatedly isolated from the nasal cavity of living wild and domestic animals 
however there are conflicting results concerning the agreement between deep and 
superficial nasal swabs (8, 10).  Standardization of sampling techniques is important in 
cross species studies; given the lack of data for agreement between the sampling 
techniques in wild mammals it should be noted that samples collected from living 
animals differed from those samples collected post-mortem.  The sensitivity of nasal 
culture in animals is unknown and it is possible that the organism is missed during a nasal 
swab, or that infection is present in a site other than the nasal passage.  Antigenemia but 
failure to isolate the organism from the nasal cavity has been reported in asymptomatic 
animals (8) and clinical cases (Duncan, unpublished).  The methodology used in this 
study may not be sufficient to identify exposure or infection in all animal samples.   
 
The prevalence of nasal colonization observed in horses in this study is similar to that of 
companion animals; however, there has been only one case of clinical C. gattii infection 
diagnosed in a horse on Vancouver Island to date (Raverty, unpublished).  This 
discrepancy may reflect differing species susceptibility to clinical disease or failure to 
diagnose clinical cases because they are not being seen by veterinarians or the diagnosis 
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is being missed.  In companion animals, feline cases outnumber disease in canines by 
over 50% suggesting a variation in species susceptibility (Duncan, unpublished).  Horses 
may be less susceptible to clinical disease than either dogs or cats.     
   
Age of horse, breed, underlying health problems, duration at sampling location and on 
Vancouver Island, average time spent outside per 24 hour period, source of hay and 
feeding methods were not identified as statistically significant risk factors for nasal 
colonization with C. gattii in this study.   It is important to note however that there were 
not enough positive horses in this study to make significant conclusions regarding risk 
factors.  While geographic location relative to environmental organism is likely the most 
significant variable influencing exposure, it is important to identify other risk factor, if 
present, such that owners and veterinarians can attempt to mitigate risk where possible. 
 
The recent emergence of C. gattii in western Canada dictates the need to identify the 
population at risk.  Wildlife and horses, by virtue of living outdoors all or most of the 
time and therefore being constantly exposed to airborne organism, may be a better 
‘environmental indicator’ of human risk than companion animals.  The collection of nasal 
swabs from wildlife species or horses residing within endemic regions of BC may be an 
inexpensive way to survey the environment and quantify environmental load.  To date 
only one horse has been diagnosed with C. gattii infection on Vancouver Island (Raverty, 
unpublished).  The impact of environmental Cryptococcus spp. on wildlife of BC remains 
largely unknown; further investigation is warranted.   
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Table 6.1: Species, age and number of wild animals tested for Cryptococcus gattii 
Species Number Age   
    Adult Juvenile 
Harbor seal (Phoca vitulina)  22 0 22 
Cottontail rabbit (Sylvilagus spp.) 20 4 16 
Black Tailed Deer (Odocoileus hemionus) 15 4 11 
Eastern Grey Squirrel (Sciurus carolinensis) 16 12 4 
North American river otter (Lutra canadensis)  6 6 0 
Red squirrel (Tamiasciurus hudsonicus) 2 1 1 
Deer mouse (Peromyscus maniculatus) 2 2 0 
Raccoon (Procyon lotor) 2 0 2 
Black Bear (Ursus americanus) 1 0 1 
Domestic rabbit (Oryctolagus cuniculus) 1 1 0 
Marten (Martes americana) 1 1 0 
Rat (Rattus rattus) 1 1 0 
Vancouver Island marmot (Marmota vancouverensis) 1 1 0 
Vancouver Island wolf (Canis lupus) 1 1 0 
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7. Discussion 
 
The emergence of Cryptococcus gattii in Canada contradicts previously accepted ecology 
of the organism.  Variables influencing clinical disease caused by this ‘new’ pathogen 
were largely unknown and prompted physicians, veterinarians, microbiologists and 
epidemiologists to explore the changing picture of cryptococcosis in British Columbia.  
Information fundamental to understanding C. gattii infection includes knowledge of the 
population at risk, characterization of the infecting organism, spatial and temporal 
distribution of disease and a better appreciation for variables driving emergence of the 
pathogen in this new environment.  The previous chapters address some, but not all, of 
the problems related to the emergence of C. gattii in Canada. 
 
Through record reviews of veterinary laboratories and human diagnostic services a series 
of presumed or confirmed C. gattii cases was compiled and presented in chapter two; this 
data reflects the general pattern of host, spatial and temporal distribution of clinical 
disease in 1999-2003.  During this time period there was an increase in the annual 
number of animal cases diagnosed while the human cases plateaued in the later years; no 
seasonality was observed.  There were almost 75% more animal cases than human cases 
even though it was hypothesized that animal cases are more likely to go undiagnosed or 
unreported when compared to humans.  Animal cryptococcosis cases were identified on 
Vancouver Island prior to 1999 suggesting the organism may have emerged in the region 
prior to its identification as a causative agent for human disease.  This information 
implies that animals, by virtue of increased case counts and, potentially, earlier onset of 
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disease, may serve as a good sentinel for human cryptococcosis infection and their role in 
characterizing the emergence of C. gattii in Canada should be endorsed. 
 
Chapter three further explored host characteristics influencing clinical disease and 
outcomes of canine and feline cases.  There were 50% more feline than canine cases and 
disease appeared more commonly in middle aged cats and younger dogs.  There was no 
sex predilection for either species.  The primary system involved was most commonly 
respiratory, followed by central nervous system (CNS) in both cats and dogs.  There was, 
however, a higher percentage of CNS disease in dogs relative to cats, and cats were much 
more likely to have subcutaneous or dermal masses relative to dogs.  Multivariate 
survival analysis identified only the presence of neurological symptoms as a statistically 
significant predictor of mortality; those animals exhibiting CNS symptoms were over 
four times more likely to die than those never showing neural signs.  This information 
provides a summary of information from which veterinarians can make clinical decisions 
and characterizes the disease in companion animals of western Canada.  
 
A case-control study, presented in chapter four, was used to identify host and 
environmental risk factors for clinical C. gattii infection in dogs and cats on Vancouver 
Island.  Recognized risk factors included residing within 10 kilometers of commercial 
logging or soil disruption, travel on Vancouver Island in the previous year, increased 
percentage of time spent outside a 10 kilometer radius of the home, increased animal 
activity level, owners hiking or visiting botanical gardens and knowing other 
cryptococcosis cases.  Taken together this data suggests that where an infectious agent is 
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not uniformly distributed, individual risk increases when the organism is re-distributed 
through large scale environmental disturbance, or when the animal has increased 
opportunities for exposure through travel or activity level.  Identification of risk factors is 
required before risk can be mitigated in any way; characterization of these factors for 
companion animals provides clinicians and owners with information that can be used to 
formulate diagnostic and prevention plans.  In the bigger picture these findings provide 
valuable information on the relationship between the environmental reservoir and disease 
risk.  Expansion of this study to look at risk factors for human disease, as well as 
evaluation of risk mitigation strategies (i.e. ongoing environmental fungicide trials) are 
necessary prior to development or implementation of any large scale control measures.  
 
Having characterized much of the available clinical data, the next step was to look at 
asymptomatic animals in attempt to determine the role of exposure on clinical disease.  
Serum samples and material for fungal culture were collected from dogs, cats, horses and 
terrestrial mammal species residing within the region where clinical cases had been 
diagnosed.  Nasal colonization was identified in squirrels, horses, dogs and cats.  Most of 
the animals sampled had no signs of systemic infection as determined by post-mortem 
examination or cryptococcal antigen testing.  This suggests environmental exposure and 
not infection with the organism.   
 
A greater proportion of positive animals were identified in the area of Duncan, BC on the 
south east coast of the island.  This trend was observed consistently through companion 
animal, equine and wildlife sampling.  The local health area encompassing the city of 
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Duncan has had the greatest per capita number of human cases and relatively high 
numbers of both canine and feline cases.  Environmental testing has also isolated high 
concentrations of organism from regional soils.  Examination of asymptomatic animals 
may be a valuable, indirect measure of environmental organism load.  Better 
understanding of nasal colonization of animals by C. gattii is required before such a 
sampling technique could be employed.   
 
From a clinical standpoint one of the most important questions warranting further 
investigation is into variables influencing the transition from asymptomatic nasal 
colonization to clinical disease.  Asymptomatic infection, defined as the presence of 
cryptococcal antigen in the bloodstream in the absence of clinical symptoms, was 
identified in a small number of dogs and cats.  Fourteen months of follow-up testing of 
asymptomatic animals revealed that animals can progress to clinical disease, remain sub-
clinically infected or clear the organism.  Given that environmental C. gattii is unlikely to 
disappear from the region, and that its airborne nature can expose a large population of 
individuals to infectious organism, it seems that an important, but poorly understood, part 
of the pathogenesis of disease is how the organism can infect some exposed individuals 
but not others.  Given the low prevalence of nasal colonization observed in all species 
tested in this research it would be difficult to obtain adequate samples from field data to 
explore this problem.  Experimental infection in animals under standardized conditions is 
necessary to effectively address this question.   
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The results of this research emphasize the role of animals in the study of emerging 
disease.  Identification and reporting of animal cases assisted public health authorities and 
microbiologists to define a geographical area in which to focus investigation efforts.  
Recent identification of animal C. gattii cases in Washington, USA (M. Leslie, pers. 
com., 2005) dictates the need for research into the pattern of disease as it spreads to a new 
country.  Information gained through the Canadian investigation will be central in the 
development of surveillance strategies in the United States and elsewhere.   
 
Given the rate of change in human ecology worldwide it may be assumed that emerging 
infectious diseases of man and animals will remain a concern for centuries to come.  
Before we can effectively prevent, or even begin to understand new or re-emerging 
infection we must take a step back and examine the disease from the angles of host, agent 
and, increasingly, the environment.  Cryptococcus gattii has afflicted less people and 
animals than vehicular traffic on the island’s major roadways; however its emergence in 
Canada is unprecedented and may reflect the changing social and ecological environment 
in the region.  Without a better understanding of variables driving emergence we will be 
lack the tools necessary to effectively manage future diseases.  In the words of Louis 
Pasteur, ‘the microbe is nothing, the terrain is everything’. 
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Appendix 1:  Interview Form 
 
Case name:  __________________________ 
Animal Name:  __________________________ 
Species:  __________________________ 
Address:  __________________________ 
Telephone:  __________________________ 
Case Number:  __________________________ 
Date of Diagnosis __________________________ 
Status of animal  __________________________ 
………………………………………………...................................................... 
Section A.  RESPONDER 
A.1 Who is responding to this interview?  
Primary care giver 
Other (Who_________________________) 
 
Section B.  DEMOGRAPHIC INFORMATION 
The following are general questions about you and your animal:  
  
B.1. What is animal’s date of birth?   _____/______/______   (d/m/y) 
 
B.2  Age years:   ____________ 
 
B.3 Animals Sex:  
Intact Male           Neutered male  
Intact Female       Spayed female   Unknown  
 
B.4 Species:  
Dog (Specify Breed) _____________________________________ 
Cat (Specify Breed) ______________________________________ 
 
 
B.5 How many did you have during the 6 month exposure period? 
   Dog(s) ____  
   Cat(s) ____     
   Bird(s) ____ 
   Ferrets(s) ____  
      Other ___________________________________ 
 
B.6 Are you living at the same address as you were during the 6 month exposure period? 
  Yes                       No  
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B.7 If yes, what is your present home address? (where animal physically lives) 
 Street ____________________________ 
 City ____________________________ 
 Postal Code  ______________________ 
 
B.8 If no, What was your previous address where you lived with your pet? 
 Street ____________________________ 
 City ____________________________ 
 Postal Code  ______________________ 
 
B.9 Estimate the following in terms of percent of the animals typical 24 hour day: 
Confined to the house                   __________h  =  ________% 
Confined to a cage/kennel outside __________h  =  ________% 
Confined to a fenced-yard              __________h  =  ________% 
Outside on controlled walks          __________h  =  ________% 
Outside on ‘off leash’ walks         __________h  =  ________% 
 
 
 
 
 
   
WHERE? 
Allowed to roam outside freely     __________h  =  ________% 
 
B.10 Overall, what percent of a 24 hour day does the animal spend outdoors? ________% 
 
B.11  In an average week what proportion of time does your pet spend outside of an area 
  10km (6 miles) around your home?               ___________%  
 
B.12 How many years has your pet/animal lived in municipality of residence?  
________# years                        Don’t know 
 
B.13. Six months before your pet became ill with CD  _______ to __________ 
Did your pet live within less than a mile of a:  
 Yes No Not Sure Refused 
Wooded area     
Farm 
If YES, what type of farm
    
       
B.14 Has your pet lived within 10 km (6 miles) of an area of soil disturbance (excavation, 
building, pipe laying etc) in the 6 months prior to illness:   
 
 No Yes, where? Excavation by whom? 
(________to ________)    
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B.15 Has your pet lived within 10 km (6 miles) of an area of logging or vegetation 
clearing during the 6 months prior to illness: 
 No Yes, where?  By whom? 
(________to ________)    
 
Section C.  ACTIVITIES 
 
C.1 Was your pet involved in any of the following activities 6 mo. before becoming ill? 
Activity Yes  No DK refused
Hunting (as a predator)     
Digging in soil      
C.2 Do you grow, or does your pet have contact with eucalyptus trees?  Yes    No 
 
C.3 Have you or your pet used any of the following types of products that may have 
contained eucalyptus? 
 Yes No Not Sure Refused 
Oil     
Soap     
Shampoo     
Air freshener     
Other, specify     
 
C.4 Were eucalyptus cuttings brought into the pet's home (for flower arrangements etc)  
  Yes                              No  
 
C.5 Was wood (eg for burning etc) or other vegetation brought into the home?   
 No       Yes      What type? _________________ Source? ______________ 
 
C.6 Six months prior to your animals diagnosis with CD were you involved in any of the 
        following activities:  
 Yes 
 
No 
 
Pet 
accompanied 
Not 
Sure 
Construction     
Outdoors House/building repair     
Cleaning bird roosts     
Handling birds (pigeons or other)     
Digging soil      
Cutting/chopping wood     
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Pruning or branch clean up     
Hiking 
If YES, Times/year  __________ 
             Where hiked
 
    
Visit a botanical garden 
If YES, where 
    
Gardening 
IF YES GO TO C.7 ELSE C.8. 
 
    
 
C.7 Did you garden: 
 Year round            Spring            Summer              Fall            Winter 
     
C.7.1 How many days a week did you garden 3 months prior to your animal’s illness? 
 1-3                 4-5                  6-7                 Don’t know 
 
C.7.2 Did you do your gardening: 
 Indoors (greenhouse or in the house)      Outdoor       Both        Don’t know 
 
C.7.3 What kind of garden did you have (Mark all that apply)? 
  Vegetable  Flower   Tree   Other (specify) ____________Don’t know 
 
C.7.4 Did your animal come in contact with: 
 Compost     Y      N   Commercial fertilizer  Y   N  
 Bark Mulch Y      N   Purchased topsoil Y   N  
 
C.8 Travel History: Where have you traveled with your pet… 
 In the last year 
On Vancouver Island 
 
 
 
 
Off of Vancouver Island 
 
 
 
 
   
C.9 Do you know of anyone or another animal that has been diagnosed with 
cryptococcosis? 
      Yes          No              
 Person    Animal            Who was it?____________________________ 
 Don’t know       Refused   When did that case occur? ___________   
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Section D. PETS MEDICAL INFORMATION 
D.1 Who is your regular veterinarian? 
    Vet’s Name ___________________________ 
    Address ____________________________________ 
 
D.2 In the past year, has your pet seen more than one veterinarian: 
 At the same _______ or different clinics ________ 
    Vet’s Name ___________________________ 
    Address ____________________________________ 
     
    Vet’s Name ___________________________ 
    Address ____________________________________ 
 
D.3 How many veterinarians did your pet see before CD was diagnosed?  ___________ 
 
D.4 If they own/have in the house more than 1 animal 
 D.4.1 Have any other of your animals been sick?    
Yes             No             Don’t know      Refused 
 
  D.4.1.1 If Yes, What type of illness ____________________________ 
  D.4.1.2 Did they visit a vet?   
Yes           No              Don’t know         Refused 
 
Section E.  PETS MEDICAL HISTORY      
 
E.1 Has your pet ever been diagnosed by a veterinarian with any of the following medical 
conditions before he/she had CD?  
 Yes No Not Sure Refused 
Pneumonia     
Chronic lung problems     
Diabetes (if YES do you give insulin)     
Skin infections     
Ear infections     
Arthritis     
Liver disease     
Kidney disease     
Cancer, specify 
IF YES, what treatment: Chemo; surgery; DK 
    
Other fungal infections (list) 
 
    
Allergies 
If Yes, What treatment 
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Immunocompromising condition (FIV, FeLk)     
Skin growths or lumps     
Other, specify 
 
    
E. 2 Has your pet been vaccinated in the past year?  Yes       No    
 Date of last vaccination? 
 
E.3 What has your animal been vaccinated for? 
 Vaccine Yes No DK 
Dogs 
DA2PP    
 Rabies    
 Kennel cough    
 Lyme disease    
 Other    
Cats 
Feline leukemia    
 Feline Distemper (Panleuk)    
 Feline Respiratory disease    
 Rabies    
 Feline Infectious Peritonitis    
 Other    
 
E.4 In the year before the diagnosis of CD was your pet on steroids for health problems?  
            Yes               No              Don’t know          Refused  
 
E.5 When did your pet’s symptoms first start? (mm/yy) ___________  
 
E.6.1 Was your pet treated for CD:   Yes      No  
 
E.6.2 How many weeks or months did you give him/her the medication(s)?   
 Refused # weeks # months 
Amphotericin B    
Ketoconazole     
Fluconazole     
Itraconazole    
Other 
If YES, please specify: 
 
   
 
E.7 Has your pet received any medications in the last year?   
   Yes      No  
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If YES date, condition treated and drug used. 
 113
 
E.8 Did your pet receive any supplements prior to diagnosis with CD?   
   Yes      No  
 
 
 
 
If YES, what and how often. 
E.9  The following question to identify any events in your pets life that may have caused 
significant ‘stress’.  During the last year have any of the following ‘potentially stressful’ 
events taken place in your pets environment? 
 Yes No DK Refused
Significant change in environment     
Illness or injury     
Kennel stay     
Any other events that put your pet ‘out of sorts’?  
Describe 
 
 
    
 
E.10  The following question series relates to your pets behavior and personality.  On the 
4 point scale 1 = very low, 2 = low, 3 = quite high, 4 = very high 
 
E.10.1  Describe your pets activity level when outside the house and restrained (leash) 
 1     2   3   4 
 
E.10.2  Describe your pets activity level when outside the house and not restrained 
 1     2   3   4 
 
E.10.3  Describe your pets activity level when inside the house 
 1     2   3   4 
 
E.10.4  How agitated is your pet in response to strangers or environmental changes? 
 1     2   3   4 
 
Section F: FOLLOW UP DETAILS 
F.1 May we contact you again should the need arise? (Environmental samples) 
Yes                             No 
 
This is the end of the formal interview.  Do you have any questions for us? 
Thanks again. Good bye. 
************************************************************************* 
F.2 Date of interview (dd  /mm /yyyy)_____/______/_____ .........................................  
F.3 Time of interview (hh:mm) :______________      am         pm 
F.4 Length of interview:______________Hrs__________________minutes 
F.5  Interviewer’s Name: (please print) _______________________________________ 
